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Hereditary non-polyposis colorectal cancer (HNPCC) describes a unique 
inherited clinico-pathological entity, caused by a mutation in anyone of a set of 
genes that are known to monitor the fidelity and facilitate repair of DNA, the 
mismatch repair (MMR) genes. 
To date, surgery is the mainstay treatment for HNPCC. Adjuvant chemotherapy 
and radiotherapy are often used to reduce systemic and locoregional 
recurrence, respectively, after curative surgical resection. The main 
chemotherapeutic agent is 5-Fluorouracil (5-FU). Studies have attempted to 
elucidate whether the MMR status of a colorectal cancer (CRC) cohort will 
define a response to 5-FU therapy. However, no difference in long term 
response or survival after 5-FU treatment between patients with MMR-proficient 
and MMR-deficient tumours were detected. 
Individual patients can vary in their response to 5-FU. A genetic susceptibility 
to adverse drug effects is purported to exist. 5-FU is mainly catabolised in the 
liver by the enzyme dihydropyrimidine dehydrogenase (DPYD) and 5-FU 
metabolites interacts with the enzyme thymidylate synthase (TYMS). Thus 
polymorph isms in the genes (DPYD, TYMS) encoding these enzymes might 
influence the efficacy of 5-FU. 
The current pilot study set out to utilise a range of informative sources and 
molecular techniques, in order to identify the opportunities and challenges in 
setting up any comprehensive cohort study and to develop a set of 
pharmacogenetic assays pertinent to the use of 5-Fluorouracil (5-FU) in the 
treatment of colorectal cancers. Additionally this study evaluated in a pilot 
cohort, whether CRC patients with a defective MMR system respond differently 
to the chemotherapeutic agent, 5-FU, than their MMR efficient counterparts. 











treatment, treatment outcomes and 5-year survival evaluated. In addition, five 
polymorph isms in TYMS and DPYD, were genotyped, in an attempt to 
determine the frequencies of the variants in patients and controls of Caucasian, 
Black and Mixed Ancestry in South Africa. 
Kaplan-Meier analysis determined that local or distant recurrence of cancer was 
not a function of chemotherapeutic intervention with 5-FU in either MMR 
proficient or deficient individuals. The current study also contributes knowledge 
about the frequency of five variants within two important pharmacogenes, 
DPYD and TYMS in the larger CRC affected SA population. The ultimate 
analysis of the pharmacogenes should be regarded as a pilot study, setting a 
template for future larger scale studies. 
This study is also a critical survey of the referral system at Grootte Schuur 
Hospital and The University of Cape Town, in order to identify means of 
streamlining data and sample capture for the future. Furthermore, this research 
contributes substantially to form part of a future network of population-based 
registries until such time that the government passes legislation to make cancer 
a notifiable disease. 
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PLAN OF THESIS 
This thesis represents research carried out towards an M.Sc. (Med) degree, 
with the specific aim of i) understanding the heterogeneity of colorectal cancer; 
ii) identifying the patterns of referral within the academic and service centers; 
iii) understanding the treatment of colorectal cancer iv) assessing treatment 
outcomes and v) providing an overall critique of the process. 
The dissertation is divided into several chapters and the layout is as follows: 
Chapter one provides some background information about colorectal cancer 
(CRC), more specifically about the inherited form, hereditary non-polyposis 
colorectal cancer or HNPCC. Additionally chemotherapeutic interventions for 
CRC is discussed as well as the utility and implication of pharmacogenomic 
studies of the agent, 5-Fluorouracil. 
Chapter two is the experimental aspect of the study. It comprises the various 
methods utilised in ascertaining the study cohort, and the methods whereby 
specific variants in drug metabolising genes for 5-FU were analysed in a pilot 
cohort. Furthermore, this chapter contains the statistical analyses performed 
after the various genotypes for the variants were ascertained for the study 
cohort. 
Chapter three provides the results from the analyses described in chapter two. 
The thesis is concluded in Chapter four, which provides comments and critique 
on each of the abovementioned aspects that the study aimed to accomplish, 













1.1 Epidemiology of Cancer 
Cancer is a life threatening disease which affects nearly 6.7 million people 
world-wide each year. Almost 10 million people are diagnosed every year, 
and it is estimated that, globally, there are 24.6 million people living with 
cancer at present (Parkin et al. 2005). Lung cancer has the highest 
incidence (1.35 million) and is the leading cause of cancer-related deaths 
(1.18 million) (Albrecht 2006). Colorectal, prostate, breast and bladder 
cancer are predominant in developed countries, whereas developing 
countries such as South Africa (SA) present with more cervical, stomach, 
liver, and esophageal cancers (Albrecht 2006). 
In 1998-9, the five most prevalent cancers in males in SA were reported to be 
those of the prostate, lung, oesophagus, colorectum and bladder. In females 
the most prevalent cancers were those of the breast, cervix, colorectum, 
oesophagus and lung (Mqoqi et al. 2004). 
Parkin et al. (2005) have suggested that cancer cases are severely under-
reported in SA. Nearly 60,000 new cancer cases were reported to the 
National Cancer Registry (NCR) in 1999 (Mqoqi et al. 2004), however, 
mortality data from the Burden of Disease Research Unit of the Medical 
Research Council (MRC), states that nearly 66,000 deaths were caused by 
cancer in 2000 (Bradshaw et al. 2004). Thus the published mortality rates 
are higher than the reported incidence (Mqoqi et al. 2004; Bradshaw et al. 
2004). It is estimated that the annual incidence could realistically be closer to 
114 000 cases per annum and that cancer surveillance by the NCR only 
covers approximately 52% of the cancer population (Albrecht 2006). 
Moreover, the National Department of Health (NDOH), which governs the 
Disease Notification System under the auspices of the Directorate: 
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in South Africa (http://www.doh.gov.za/docs/dns-f.html). because of the 
overwhelming burden of communicable diseases. Hence cancer is under-
emphasised, with 33 medical conditions, such as cholera, malaria and 
tuberculosis preferentially demanding priority with the NDOH. Patient data is 
intermittently reported to the NCR on a goodwill basis only, and the quality of 
the data is variable (Parkin et al. 2008). However, cooperation has been 
sporadic due to patient confidentiality issues. The registry has not been 
updated since 1999 and contains only histological diagnoses as well as 
demographic data, and no geographic information (Albrecht 2006). 
It is evident that, currently, cancer can only be monitored by mortality data 
failing accurate incidence reporting as indicated by the disharmony in the 
mortality and incidence rates. Unfortunately, cause of death certification and 
registration in SA is of poor quality, and has been cited by the World Health 
Organisation (WHO) to be incomplete, ill-defined and under reported 
(Mathers et al. 2007). Despite recent improvements, and overcoming a 
backlog of cause of death statistics production, the accuracy of death 
registration is still poor. A high proportion (92%) of death notification forms 
from the greater Cape Town area contain errors (Burger et al. 2007). Burger 
et al. (2007) have recommended that clinicians should primarily be better 
trained in death certification in order to alleviate the certification error rate. 
1.2 Colorectal Cancer (CRC) 
Colorectal cancer (CRC) accounts for approximately 9.4% of the total 
number of cancer cases diagnosed globally (Parkin et al. 2005). The 
occurrence of CRC in developing countries as in Africa, is low in comparison 
with other developed countries such as the United States of America (USA), 
Australia, Europe and Japan. Comparative mortality data in the USA and SA 
revealed that the incidence of CRC is 200-300% lower in SA than in the USA 
(Albrecht 2006). This geographical difference is probably largely due to 
different environmental exposures such as diet and lifestyle, although the 
effect of under reporting of cancer in SA should not be excluded. Of the 












1200 are CRC cases (Mqoqi et al. 2004) which translates to about 11.3 
males per 100,000 and 8.3 females per 100,000 being diagnosed with this 
form of cancer (Parkin et al. 2005). CRC has, despite a high incidence 
worldwide, relatively low mortality rates in both males and females in SA 
(Albrecht 2006). 
1.2.1 Inherited CRC 
A large body of evidence shows that some individuals have an increased 
predisposition to developing CRC. This is most clearly seen in the familial 
forms of the disease, which collectively account for approximately 10-15% of 
all CRC; namely familial adenomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC), or Lynch syndrome (Vasen 2005). A 
short introduction to FAP will follow, but the focus of this review and the 
subsequent study, will be on HNPCC. 
A) Familial adenomatous polyposis (FAP) 
Clinically, patients with FAP present with thousands of adenomatous polyps 
in the colon, and although mostly benign, they have malignant potential. 
Extracolonic manifestations of FAP include brain tumours and retinal lesions 
(Arnold et al. 2005). The molecular pathogenesis is attributed to causative 
mutations in the APe gene, which is located on the long arm of chromosome 
5 (Herrera et al. 1986; Kinzler et al. 1991). 
B) Her ditary non-polyposis colorectal cancer (HNPCC) 
HNPCC describes a unique inherited clinico-pathological entity, caused by a 
mutation in anyone of a set of genes that are known to facilitate the repair of 
DNA (Lynch et al. 1993). Lynch and colleagues described this hereditary 
disease which is also known as Lynch syndrome, although it was first 
reported by Aldred Warth in in 1913 (Lynch et al. 1993). HNPCC is an 
autosomal dominant disease accounting for nearly 4% of all CRC (Sarnetson 
et al. 2006). Clinically, Lynch syndrome is classified into two major groups; 
Lynch syndrome types I and /I, based on the absence or presence of extra-















characterised by tumours mostly in the proximal colon, whereas Lynch II 
manifests with extra-colonic cancers such as those of the ovaries, 
endometrium, small bowel, pancreas and brain. More recently, the existence 
of a third group, Lynch Syndrome III, was proposed by Felton et al. (2007). 
This group comprises patients presenting with a different spectrum of early 
onset cancers, as a result of homozygous or compound heterozygous 
mutations in one of the mismatch repair genes. These patients present with 
brain or haematological malignancies early in life. Biallelic, germline 
mutations in these genes also result in greatly impaired MMR function, 
necessitating a distinct classification based on molecular pathology and site 
of cancer (Felton et al. 2007). 
i) Clinical diagnosis of HNPCC 
HNPCC is a heterogeneous disease, and as such, no single defining feature 
exists on which diagnosis can be based. Instead, the clinical diagnosis of 
HNPCC is facilitated by considering family history, histopathology and age at 
onset, as set out in the Amsterdam and Bethesda criteria. 
In 1991, the International Collaborative Group on HNPCC (ICG-HNPCC) 
developed the Amsterdam Criteria in order to accurately define HNPCC for 
comparative studies. At the time, the consensus was to diagnose HNPCC 
based on the following minimum criteria: i) at least three relatives should 
have a histologically verified CRC, one of whom is a first degree relative of 
the other two; (ii) at least two consecutive generations should be affected; 
and (iii) in one of the relatives, CRC should be diagnosed before the age of 
50 years (Vasen et al. 1991). Therefore, HNPCC is broadly defined as 
"colorectal cancer in multiple family members from multiple generations, with 
cancers arising, on average, in the fifth decade" (Lynch and Smyrk 1998). A 
major weakness of the Amsterdam Criteria was the exclusion of extracolonic 
malignancies in the diagnosis, since the incidence of cancers of the 
endometrium, small bowel, stomach, kidney and ovary is increased in 
HNPCC (Lynch and Smyrk 1998). For this reason the Amsterdam II Criteria 
included all malignancies associated with HNPCC. Some patients with CRC 
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do not meet the Amsterdam criteria for HNPCC and hence could not be 
distinguished from sporadic CRC. This necessitated another set of criteria, 
the Bethesda guidelines, to be developed which describe all clinical 
conditions, diagnosed before age 45, for which screening of tumour tissue 
DNA for the presence of microsatellite instability (MSI) or immuno-
histochemical staining (IHC) is indicated, in order to identify potential HNPCC 
patients (Rodriguez-Bigas et al. 1997). The revised Bethesda criteria was 
later instituted to include all patients who were less than 60 years of age and 
diagnosed with cancer (Umar et al. 2004). 
ii) Molecular pathogenesis of HNPCC 
In each cell, complex enzymatic systems exist which monitor DNA damage 
and replication errors. The mismatch repair (MMR) system is comprised of 
several proteins that work together to monitor the fidelity of DNA and act as 
tumour suppressor genes (Hemminki et al. 1994). Carcinogenesis may 
result from compromising any component of this critical enzymatic system, as 
is reflected in the molecular pathogenesis of HNPCC. HNPCC is caused by 
the mutational inactivation of both alleles of a MMR gene. The one allele is 
usually inactivated by an inherited/germ-line mutation, whilst the other may 
be rendered non-functional by an acquired somatic mutation. The acquired 
mutation is also referred to as the "second hit" since the result is a complete 
loss of function for the MMR gene in question (Nystrom-lahti et al. 1994; 
Peltomaki 1997). 
The postreplicative correction of mismatches and insertion/deletion loops has 
been attributed to five pivotal MMR genes viz. MLH1, PMS2, MSH2, MSH3 
and MSH6 (Hemminki et al. 1994; Jiricny and Nystrom-lahti 2000). 
Functional studies in Escherichia coli (E. colJ) and Saccharomyces cerevisiae 
have contributed to our understanding of the intricate workings of the human 
MMR system. This has been fully reviewed in Jacob and Praz (2002) and 
will only briefly be discussed. The E. coli MMR system is mediated by the 
complex interaction of three proteins: MutS, Mutl and MutH, encoded by 
genes mutS, mutL and mutH. MutS effiCiently recognises mismatches and 












MutL, facilitated by an ATP-directed conformational change and enables 
repair. The five human homologs of MutS, with partly redundant functions, 
are MSH2, MSH3, MSH4, MSH5 and MSH6. Only MSH2, MSH3, and MSH6 
collaborate to repair nuclear DNA. MSH4 and MSH5 are responsible for 
other important cellular functions (Bocker et al. 1999; Edelmann et al. 1999). 
During repair, MSH2 forms heteroduplexes with MSH3 and MSH6 to form 
MutS~ and MutSa, respectively (Acharya et al. 1996; Alani 1996). In human 
cells, MutSa is present in much higher levels than its twin, MutS~, and as 
such, the majority of mismatch recognition is performed by MutSa. MutL has 
four human homologs, namely MLH1, MLH3, PMS1 and PMS2. MutSa, or 
alternatively, MutS~ can interact with MutLa (heterodimer of MLH 1 and 
PMS1) or MutL~ (heterodimer of MLH1 and MLH3), depending on the type of 
mutation (Rasch Ie et al. 1999). A ternary complex is thus formed, consisting 
of the mismatch, MutSa/~ and MutLa/~ which allows for strand discrimination 
and removal of the erroneous base (Prolla et al. 1994). 
Currently, information on mutations and polymorph isms in the MMR genes 
are maintained in several databases including The Memorial University of 
Newfoundland Mismatch Repair Genes Variant Database 
(http://www.med.mun.ca/MMRvariants), and INSiGHT (www.nfdht.nl), 
curated and maintained by the ICG-HNPCC. More than 448 mutations in the 
MMR genes have been implicated in HNPCC and, of these, nearly 50% 
occur in MLH1, 39% in MSH2 and 7% in MSH6 (Peltomaki 1997; Jiricny and 
Nystrom-Lahti 2000; Marcos et al. 2006; http://www.nfdht.nl). 
iii) Molecular diagnosis of HNPCC 
Patients who meet the Amsterdam or Bethesda criteria, and are suspected of 
having HNPCC, are subjected to several molecular analyses in order to verify 
the diagnosis. Generally, screening involves testing the DNA from tumour 
tissue for MSI. Additionally, IHC staining for the MMR proteins of colorectal 
cancer specimens from suspected HNPCC patients can be performed as an 
alternative method of screening. Loss of MMR protein expression may 
reflect a pathogenic mutation in the MMR genes (Arnold et al. 2004). If there 
are noticeably lower levels of any of the MMR proteins in tumour tissue 
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compared to normal tissue, targeted mutational analysis of that specific gene 
can be performed to identify the pathogenic mutation. 
Tumorigenesis in a cOlonocyte can be driven by a particular pattern of DNA 
damage, resulting in normal cells being transformed to tumour cells. Most 
tumours from patients with HNPCC show genomic instability or MSI, and this 
has been attributed to inactivation of the MMR system that is responsible for 
maintaining fidelity during DNA replication (Boland et al. 1998). If the 
caretaker function of the MMR system malfunctions, errors that occur during 
DNA replication are not repaired, and mutations are allowed to accumulate. 
Simple repetitive sequences, called microsatellites, that are omnipresent in 
the genome, are used to gauge the extent of mismatch repair deficiency, 
giving rise to the phenotype termed MSI (Bhattacharyya et al. 1994; Boland 
et al. 1998). MSI studies in human colorectal adenocarcinoma cell lines have 
provided evidence of a 100-fold increase in mutation rates (Bhattacharyya et 
al. 1994; Branch et al. 1995). Mutations within key genes, resulting in loss of 
protein function, are thought to contribute to tumorigenesis. It should be 
noted that a proportion (15%) of non-hereditary, or sporadic, colorectal 
tumours also show MSI (Boland et al. 1998). The absence of MMR proteins 
in such samples after IHC may be due to hypermethylation of the MMR 
promoter (Valle et al. 2007). When an allele is hypermethylated, it may either 
repel transcription factors or it may attract proteins that inhibit transcription, 
resulting in down-regulated expression (Bartolomei and Tilghman 1997). 
Once the cytosin  residue of a CG dinucleotide couple - contained within 
CpG islands in promoter regions - is methylated, the gene is 
transcriptionally silenced (Niv 2007). 
MSI at a particular marker is defined as a change of any length, due to either 
the expansion/contraction of repeating units in a microsatellite within tumour 
DNA, when compared to normal tissue (Boland et al. 1998). The 
recommended panel of markers is composed of two mononucleotide repeats 
(BA T26 and BA T25) and three dinucleotide repeats (05S346, 02S123 and 
017S250) that should be investigated in order to report on the mutator 












of the markers (two or more of the five microsatellite sequences) are 
designated MSI-high (MSI-H), whereas those showing only one of the 5 
markers to be mutated are designated MSI-Iow (MSI-L). A third specific 
tumour phenotype was described as MS-stable (MSS), where there was no 
evidence of MSI (Boland et al. 1998). 
1.3 Cancer Management 
Patient care in South Africa comprises an interaction between private and 
state-funded facilities. Patients who have healthcare insurance, usually 
through employment, are treated in the private sector, whilst the majority of 
individuals (85.7%) are provided for in the public sector (General Household 
Survey 2007). Both sectors are expected to provide high-quality care, 
however the latter are often under-resourced due to lack of appropriate state 
funding. Patients diagnosed with any cancer, including CRC are first 
assessed for treatment, whether this is curative or aimed at improving quality 
of life (Abratt and Vorobriof 2003). In South Africa, the stage of cancer, 
according to the Dukes' staging system, determines whether chemotherapy 
is appropriate. For instance, patients newly diagnosed with Dukes stage C 
CRC (an invasive tumour with some nodal metastases) at Groote Schuur 
Hospital (GSH), Cape Town, usually undergo surgery to remove the bulk of 
the tumour growth. Thereafter, patients are generally treated with adjuvant 
(defined as "after surgery") chemotherapy to prevent systemic recurrence. 
With Dukes stage D CRC, distant metastatic disease is present, and 
depending on their fitness, patients receive chemotherapy and are closely 
monitored to gauge whether the disease will remain stable or progress. 
Unlike private sector patients, public sector hospitals are generally unable to 
switch to chemotherapeutic agents that are effective in the refractory setting 
in the event of recurrence or disease progression, and most patients must 
resort to symptom-directed care (Goldberg et al. 2007; Dr B Robertson, GSH 














For the last forty years there was only a single chemotherapeutic agent, 5-
Fluorouracil (5-FU), in the armamentarium for treating colorectal cancer. 
Today, however, the strategies and drugs are relatively plentiful. In order to 
enhance the cytotoxicity of 5-FU, biochemical modulation by other agents are 
applied, resulting in a continuum of management possibilities. Some 
regimens either alter the metabolism of 5-FU, or result in the retention of 
active metabolites in the cell. Drugs in this category include Leucovorin and 
Methotrexate. Another category focuses on agents which will produce 
synergistic effects, resulting in greater cytotoxicity. Oxaliplatin falls into this 
class. Lastly, strategies that alter the pharmacokinetics of 5-FU (e.g 
Capecitabine) are also utilised (Grem 2000). However, not all strategies have 
proven to be successful. It is still unclear which patients should receive which 
drug to attain the best possible outcome. Some of the most popular 5-FU 
drug additives, mediating cytotoxicity, shall be discussed. 
A) CRC and chemotherapy 
Unlike for cervical cancer, which is frequently caused by the human papilloma 
virus, no vaccine exists against CRC (Markowitz et al. 2007). The US Food 
and Drug Administration (FDA) (http:/www.fda.govl) has approved the use of 
Capecitabine, 5-FU, Irinotecan, Levamisole, Oxaliplatin and Leucovorin to 
treat CRC in the USA. Currently, despite a plethora of chemotherapeutic 
agents being available, the mainstay regimen for CRC and by default, 
HNPCC, in state-funded hospitals in Cape Town, involves 5-FU. In SA, the 
popularity of 5-FU as a chemotherapeutic agent for CRC, is mainly because it 
is relatively inexpensive and thus freely available in the public sector (Meyers 
et al. 2001). Nevertheless, apart from the response rate to 5-FU as a 
monotherapy being only 10-20%, the quality of life in patients on 5-FU is 
reported to be severely compromised, with many debilitating side effects 













B) Modulators of 5-FU to enhance clinical benefit 
i) Leucovorin 
The non-responsiveness of tumours to 5-FU as a monotherapy has forced 
oncologists and researchers to assess the use of combination and sequential 
combination therapy (Venook 2005). 
Leucovorin (LV, 5'-formyltetrahydrofolate) is a folinic acid-based biomodulator 
of 5-FU. LV contributes the co-factors needed for the interaction of the 5-FU 
metabolite, fluorodeoxyuridine monophosphate (FdUMP) with the enzyme 
thymidylate synthase (this is discussed in depth in section 1.4.1). A meta-
analysis of several clinical trials (The Advanced Colorectal Cancer Meta-
Analysis Project 1992) showed a substantial increase in response rates of 
patients on combination therapy. Patients benefitted significantly (p<0.001) 
from combination therapy (23%) in terms of tumour response rate, compared 
to single-agent 5-FU treatment (11 %). Since then, adjuvant therapy with 5-
FU has seldom been administered without LV modulation. A subsequent 
meta-analysis in 2004, which incorporated an extended follow-up period, only 
served to affirm the positive interaction between the two drugs. 
ii) Methotrexate 
Methotrexate (MTX) and 5-FU act synergistically to inhibit thymidylate 
synthase (section 1.4.1) although MTX does this in an indirect fashion. MTX 
inhibits one of the key enzymes in folate metabolism; dihydrofolate reductase 
(DHFR) (Goulian et al. 1980a). Several clinical trials were included in a meta-
analysis which has provided evidence that 5-FU modulation by MTX nearly 
doubles the response rate of patients with metastatic CRC (mCRC) (The 
Advanced Colorectal Cancer Meta-Analysis Project 1994). 
iii) Irinotecan 
Irinotecan (IR) (Camp tosa t®; Pfizer Pharmaceuticals Inc., New York, NY, 
http://www.pfizer.com) is a topoisomerase I inhibitor. Topoisomerase I is a 
nuclear enzyme which is crucial for the unwinding of DNA during replication 
and is therefore needed for cell division (Saltz et al. 2000). Douillard et al. 














with infusional 5-FU/LV, calcium folate and IR (FOLFIRI). The overall survival 
for patients on FOLFIRI was 17.4 months compared to 14.1 months for 
patients without IR, after the start of treatment. A median overall survival of 
more than 20 months for patients on FOLFIRI has since been reported 
(Kohne et al. 2004; Ji et al. 2005). 
Another study assessed the clinical benefits of IR with bolus 5-FU/LV (IFL) for 
previously untreated patients with mCRC. The IFL regimen proved to be 
more effective than the 5-FU/LV dual combination, based on its ability to 
reduce tumour size and delay disease progression. The response rates for 
patients on IFL were 50% compared to 28% for the 5-FU/LV combination and 
the overall survival was 14.8 months compared to 12.6 months (Saltz et al. 
2000). 
iv) Oxaliplatin 
Oxaliplatin (OX) (Eloxatin®; Sanofi-Synthelabo Inc., New York, NY, 
http://www.sanofisynthelabo.us) is a platinum derivative, currently part of the 
mainstay treatment regimen for mCRC in the USA. Patients who receive OX 
in combination with 5-FU and LV (FOLFOX) show great synergistic drug 
activity, having longer progression-free survival (20 months versus 14 
months) than control populations who receive only 5-FU/LV (de Gramant et 
al. 2000) or IRIOX alone (Ashley et al. 2007; Sanoff et al. 2008). Additionally, 
more than 9% of patients have a 5-year survival on this regimen (Sanoff et al. 
2008). Drug-related side effects are decreased (albeit dose dependant) when 
OX is included in the 5-FU/LV regimen with the exception of reversible 
neuropathy (Hospers et al. 2006). A combination of OX, Folinic acid, 5-FU 
and IR, however, has failed to show any significant survival benefit compared 
to Folinic acid, 5-FU and IR alone (Souglakos et al. 2006). 
v) Capecitabine 
Capecitabine (Xeloda®; Hoffmann-La Roche Inc., Nutley, NJ, 
http://www.roche.us) is an oral derivative/pre-prodrug of 5-FU with a more 
favourable toxicity profile than 5-FU. It escapes degradation and hence is 
more active in tumour tissue (Schellens 2007). It is reportedly more tolerable, 
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convenient and at least as effective as 5-FU/L V (Cassidy et al. 2002). It has 
been shown that Capecitabine has a more favourable outcome, and could 
potentially replace 5-FU as combination therapy with OX (Cassidy et al. 
2004). 
e) Targeted agents as supplement to chemotherapy for eRe 
The success of initial chemotherapeutic agents has been hampered by a lack 
of specificity and dose-dependent adverse effects. Advances in discovering 
the molecular pathogenesis of cancer, has paved the way for developing 
target-specific agents. Unlike chemotherapy, which assaults all dividing cells, 
both healthy and cancerous, some targeted therapies act at key points in the 
development of tumours, and hence focus only on cancerous tissue making 
them less harmful to normal, healthy cells. This strategy has the potential to 
also reduce the side effects associated with therapy. The success of targeted 
therapies, however, is hindered by the costs involved in treatment. 
In 2006, the UK National Institute for Health and Clinical Excellence (NICE), 
evaluated bevacizumab (Avastin®; Genentech Inc., South San Francisco, CA, 
http://www.gene.com). and cetuximab (Erbitux®; ImClone Systems Inc., New 
York, NY, http://www.imclone.com) as targeted therapeutic agents for CRC 
(Barnett et al. 2006). 
Bevacizumab (BV) is a humanised immunoglobulin G1 monoclonal antibody 
that inhibits vascular endothelial growth factor, which is a mediator of tumour 
angiogenesis (Presta et al. 1997). Angiogenesis is defined as the formation 
of tumor blood vessels, allowing tumor cells to access the systemic circulation 
and to metastasise. Tumours are unable to progress without adequate blood 
supply which provides nutrients and oxygen. Thus, the rationale behind using 
BV is that if angiogenesis is prevented, the tumour will not progress further 
(Venook 2005). 
Several clinical trials were performed to assess the efficacy of BV used in 
conjunction with chemotherapy. In a trial by Kabbinavar et al. (2003), BV was 
added to 5-FU/L V therapy, in previously untreated CRC patients. By 
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comparing it to standard chemotherapy (5-FU/LV) alone, the authors showed 
that addition of a targeted agent is successful in increasing response rates 
and prolonging survival (21.5 versus 13.8 months). Several subsequent 
studies confirmed the latter, whereby the addition of BV prolonged overall 
median survival (16.6 versus 12.9 months), progression-free survival, and 
increased the response rate by 11 % (Emmanouilides et al. 2004; Kabbinavar 
et al. 2005). In another trial, Hurwitz et al. (2004) showed that the BV/IFL 
regimen (section 1.3.1Aiii) significantly prolonged overall survival, 
progression-free survival, and response rates in therapy-naive patients. 
Patients whose regimens were supplemented with BV showed an average of 
20.3 months overall survival compared to 15.6 months for those individuals on 
a placebo. 
It has been shown that expression of the epidermal growth factor receptor 
(EGFR) in colonic carcinomas is accompanied by a more aggressive disease 
and a poor prognosis (Prewett et al. 2002). Cetuximab (CTX) is a chimeric 
IgG1 monoclonal antibody that has a high affinity for EGFR, and by binding to 
it, prevents its natural ligand from binding and inducing phosphorylation of 
EGFR. Cunningham et al. (2004) investigated the efficacy of CTX in 
combination with IR in patients with CRC who were unresponsive to 
monotherapy with IR. A significantly higher response rate (22.9%) in the 
combination therapy group was observed when compared to the 
monotherapy group (10.8%) as well as longer time to progression. 
D) A defective Mismatch Repair system influences response to 
chemotherapy 
It has been shown that HNPCC patients who present with Dukes stage B or C 
CRC, show better survival rates in general, compared to their sporadic CRC 
counterparts [87.5% versus 44.8%] (Elsakov and Kurtinaitis 2006). Thus a 
survival benefit is indicated for HNPCC patients in the absence of any 
chemotherapy (Ribic et al. 2003); in this regard one might assume that 
treatment with 5-FU is not necessarily beneficial to everyone taking it 
(Longley et al. 2003; Allen and Johnston 2005). 
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Several studies attempted to elucidate whether the MMR or MSI status of a 
CRC cohort will ,define a response to 5-FU therapy (Ribic et al. 2003; Jover et 
al. 2006). Most studies distinguished a tumour as MMR-deficient when a loss 
of e.g. MLH1 protein expression or MSI occurred. However, no difference in 
long term response or survival after 5-FU treatment between patients with 
MMR-proficient and MMR-deficient tumours were detected (Ribic et al. 2003; 
Jover et al. 2006), and patients presenting with MSI-H tumours, did not 
benefit from 5-FU treatment when compared to individuals with MSI-L 
tumours (Warusavitarne and Schnitzler 2006). Conversely, in patients 
receiving no adjuvant treatment, those with MSI-H tumours had longer overall 
survival than stage-matched sporadic cancer patients with MSI-L tumours or 
MSS tumours (Warusavitarne and Schnitzler 2006). 
Some studies have suggested that the MMR proteins mediate a response to 
other DNA-damaging agents. The trend amongst researchers has been to 
study hypersensitivity or alternatively, resistance, to cytotoxic agents in MMR-
deficient and proficient cell lines. Work with the MLH1-deficient human 
colorectal carcinoma cell line (HCT116) has been well characterised. MMR 
function restoration is accomplished in these cells by transfection of one copy 
of chromosome 3 containing the MLH1 gene into the cells. Thereafter cells 
usually manifest sensitivity to certain DNA damaging agents (Aebi et al. 1996; 
Aebi et al. 1997; Takahashi et al. 2005). 
Differential sensitivity of MMR-deficient cells to OX and cisplatin (CIS) have 
been reported (Aebi et al. 1996; Sergent et al. 2002). Carboplatin, OX and 
CIS are platinum compounds that form adducts with DNA, thereby signaling 
apoptosis (Claij and Riele 1999). Mutations in MLH1 and MSH6 result in 
resistance only to CIS, but not to OX as evidenced by the preferential 
recognition of CIS adducts over OX adducts by the bacterial MMR protein, 
MutS (Vaisman et al. 1998; Zdraveski et al. 2002). Furthermore, tumours 
obtained from ovarian cancer patients, which displayed an MSI phenotype 
and MLH1 deficiency, were reported to be resistant to CIS-based therapy 
(Watanabe et al. 2001). Thus it is expected that in vivo, MMR-deficient 













Sergent et al. (2002) published a contradictory report, citing spontaneous 
resistance to OX and CIS in colon cancer cell lines with a defective MMR 
system. It has also been shown by Anthoney et al. (1996) that MSI is not a 
causal factor in resistance to CIS, but rather a byproduct of acquired 
resistance after CIS treatment. Resistance to topoisomerase I inhibitors, 
Topotecan and IR have also been demonstrated in MLH1- and MSH2-
deficient cell lines (Takahashi et al. 2005), but contradictory evidence shows 
that MSI-H cell lines and tumours are hypersensitive to IR (Bras-Gonc;alves et 
al. 2000; Fallik et al. 2003). Thus, a variable response to several 
chemotherapeutic agents has been attributed to MMR status, and these 
inconsistent results provide scope for further research. 
It is evident that hypermethylation of the MMR genes is also associated with a 
resistance to chemotherapy. Some studies have shown that loss of MLH1 
expression, and corresponding hypermethylation of promoter CpG islands 
accompanied the acquired resistance of ovarian cancer cell lines to CIS 
(Strathdee et al. 1999; Wei et al. 2003). A landmark paper by Arnold et al. 
(2003) promotes the use of de-methylating agents in vitro to treat MMR-
deficient, MLH1 hypermethylated cell lines. In so doing, the authors were 
able to restore MLH1 expression and sensitise a 5-FU resistant cell line to 
treatment. This provides a similar effect as had previously been 
accomplished by chromosome 3-based transfections into MLH1-deficient cell 
lines. Gifford et al. (2004) showed that CpG methylation of DNA could be 
detected in blood plasma samples, and corresponded to the status in tumour 
cells. The proportion of samples in which the promoter of MLH1 was 
methylated, increased substantially after treatment with chemotherapeutic 
agents such as Paclitaxel, Carboplatin and Docetaxel. Some samples that 
had relapsed after treatment also showed increased methylation patterns 
compared to pre-chemotherapy samples, and hence the authors speculated 
that methylation is in fact acquired after chemotherapy, and contributes to 
resistance (Gifford et al. 2004). 
Several authors studied mechanisms of resistance to 5-FU in vitro. Zhu et al. 
(2005), disclosed that cells which were resistant to 5-FU over-expressed a 
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common anti-apoptotic protein, Bcl-l, although the parental lines did not. 
Expression of other members of the BcI-2 family of proteins were also 
upregulated in 5-FU resistant cells compared to 5-FU sensitive cells. 
However, these proteins are pro-apoptotic, and the authors speculated that 
the ratio of the two types of proteins might affect apoptotic behaviour after 5-
FU treatment. 
E) MicroRNA and Cancer 
MicroRNA (miRNA) are essential for temporal control of a range of post-
embryonic developmental events and form part of an endogenous RNA 
interference (RNAi) pathway (lee et al. 1993). 
Studies indicate that modification of miRNA gene expression may play an 
intricate part in the development of cancer. Therefore it is also possible that 
chemotherapeutic agents could alter miRNA gene expression patterns, given 
that most anti-neoplastic agents interfere with nucleic acid metabolism and 
gene expression. Calin et al. (2002) were the first to associate miRNA with 
cancer, and thereafter miRNA expression profiles in lung (Yanaihara et al. 
2006), breast (Ma et al. 2007) and colon cancer have been investigated. 
Calin et al. (2002) reported that several miRNA genes, referred to as miR-15a 
and miR-16a, are located in a chromosomal region that is often deleted in B-
cell chronic lymphocytic leukemias (B-Clls). The ensuing deletion analysis 
showed that miR-15a and miR-16a are located on chromosome 13q14, within 
30-kb of a region that is lost in ClL. An accompanying expression analysis 
demonstrated that the majority of Cll cases show a down-regulation of miR-
15a and miR-16a (68%). Further studies by Calin et al. (2004) included a 
systematic search to identify whether the genomic position of a large number 
of miRNAs correlate with the location of cancer associated genomic regions. 
The authors speculated that miRNA genes might be located in fragile 
chromosomal regions which are often susceptible to amplification, deletion, or 
translocation during the course of tumour development. Thus it is evident that 
normalisation of the miRNA expression pattern might result in restoration of 
the deregulated post-transcriptional control and therefore could have a 













miRNAs, including several located in regions implicated in colon cancer. 
Micheal et a/. (2003) identified two miRNAs that exhibit reduced levels in 
precancerous and neoplastic colorectal tissue. The authors' approach 
included a Northen Blot analysis on enriched small fragments of RNA from 
both a colonic adenocarcinoma and normal mucosa. Most sequences show 
similar steady-state levels of mature miRNAs, as well as precursor miRNA in 
both normal and cancerous tissues. However, the authors confirmed that 
several sequences (miR-143 and miR-145) consistently exhibit significantly 
reduced steady-state levels of mature miRNA in neoplastic epithelium as well 
as adenomatous polyps, relative to normal epithelium. The unprocessed 
precursors of both miRNA were in equal abundance in both tissues which 
implies that the reduction is due to post-transcriptional processes. The 
authors found it imperative to also establish the putative targets of miR-143 
and miR-145. Represented transcripts include components of signal 
transduction pathways, proteins involved in metabolic processes, as well as 
processing of RNAs. How the observed reduction of mature miR-143 and 
miR-145 levels is associated with the translation of these putative targets is 
still unknown. Later, Akao et al. (2006) showed that let-7 is down-regulated in 
human colon cancer cell lines and tumours. Transfection with the precursor 
miRNA of let-7, let-7a-1, caused significant suppression of growth in the 
cancer cells and suggests that let-7 miRNA is involved in growth of colon 
cancer cells. In recent years, Lanza et al. (2007) did a genome-wide 
expression analysis of microRNA in MSS and MSI-H colon cancer samples. 
They were able to produce a molecular signature of differentially expressed 
miRNA genes that could distinguish between MSS and MSI-H tumours. 
Rossi et al. (2007) hypothesised that treatment with 5-FU somehow alters 
miRNA gene expression and showed evidence to that effect. Not only were 
19 miRNA genes upregulated in colon cancer cells after 5-FU treatment, but 
three were also shown to be down-regulated. Surprisingly, miRNA genes that 
are already induced to over-express in transformed neoplastic colorectal 
tissue, showed additional drug-induced up-regulation. On the other hand, 
some miRNA genes, commonly up-regulated in tumour tissue, were down-











Other authors discuss the potential of using siRNA to enhance the 
chemosensitivity of cells to a particular drug. According to Lei et al. (2007), it 
is postulated that over expression of several anti-apoptotic proteins in cancer 
cells lead to resistance to apoptosis. The authors established that by 
silencing these proteins using siRNA, cells became more sensitive to a 
chemotherapeutic agent, and apoptosis of cancer cells was increased. Lei et 
al. (2007) used siRNA mediated silencing, in vitro, to show that cells in which 
knockdown of anti-apoptotic genes, Bcl-2 and Bcl-xl occur, displayed 
increased sensitivity to 5-FU, and hence underwent increased cell-death. 
Thus knockdown of these genes may act as a chemosensitising event. 
1.4 Pharmacogenomics of 5-FU 
As mentioned before, individual patients can vary in their response to 5-FU. It 
is thought that a genetic susceptibility to adverse drug effects may exist 
(Giacomini et al. 2007). However, before the pharmacogenomic possibilities 
of 5-FU can be discussed, it is imperative that the intercellular dynamics and 
kinetics of 5-FU is made explicit. 
1.4.1 Mechanism of action of 5-FU 
For 5-FU to exert its cytotoxic effects it must first be activated. After transport 
into the cell, 5-FU is sequentially anabolised to give several active 
compounds; fluorouridine triphosphate (FUTP), fluorodeoxyuridine 
monophosphate (FdUMP) and fluorodeoxyuridine triphosphate (FdUTP) [See 














Figure 1.4.1A: Mechanism of action of 5-FU 
(Longley er al. 2003) 
The 5-FU active compounds exert their cytotoxic function by RNA aM DNA 
directed actions. Primarily. misincorporalion of the antimelabolites into the 
RNA strand results in mRNA splicing alterations (Wilkinson and Pitot 1973; 
Wilkinson and Crumley 1977 and 1978; Kufe ef al. 1981, D00I19 aM Dolnicks 
1988). The metabolite FdUMP also behaves as a Quasi-substrate of the 
enzyme thymidylate synthase (TS) (Santi ef al. 1974; Lbnn and Lbnn 1984: 
Sawyer d al. 1984: Schuetz ot al. 1986). As previously mentioned, th is 
interaction is modulated by LV, Which contributes the GO-factors needed for 
the interaction of FdUMP with TS . Thus, these two agents are co- inhibitors of 
the TS pathway in DNA synthesis. In the cell. LV is converted step-wise to S· 
10'-methyl enetetra hydrofolate (CH,-THF). The enzyme methylene-
tetrahydrofo late reductase (MTHFR) then reduces CH,-THF to S-
methytte trahydrofolate (MrTHF) Under normal circumstances, this reaction 
would favour DNA synthesis by accelerating the TS pathway, since CH,-THF 
provides methyl groups for the nonreversible, reductive methylation of dUMP. 
However, the presence of 5-FU and its interaction with and subsequent 
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involving CH,-THF and MrTHF (Figure 1 418) (Wisotzkey et al. 1999, Sohn 
et al. 2004) . 
Fi~ure 1.4.1B : Sl,b'c !ccn,ry 
comp lex betwecn F ~ UMP, TS 
. n~ CH?-HI F (Long le y 01 a l 
2003) 
TS is translated from the TYMS gene on chromosome 18p11.32 
(NC_000018.8), producing a 313 amino acid protein which functions as a 
dimer. In unperturbed circumstances, TS serves to convert the DNA 
replica tion precLJrsor, deoxyuridine mono phosphate (dUMP) to 
deoxythymidine monophosphate (dTMP) by reduct ive methylatioo (Sant i et ill 
1974). Thymine nLJcleotides, wh ich are crucial for DNA repllcatioo , are 
thereby provided . However, dLJring chemotherapy. the collVersioo of 5-FU to 
fluorodeoxyur idine (FUDR) IS catalysed by thymidine phosphorylase , and the 
proteirl is subsequently phosphoryl8ted by thymidirle kinase to FdUMP 
(Wilkinson arid Crumley 1977, Schwarlz 81 al. 1995). FdUMP chem ical ly 
resembles the uracil moiety in dUMP, and as SLJch is a cOlnpetitive inhii)ijtor of 
this natLJral sLJbs trate of TS (Figure 1.4 1C ). FdUMP wi ll preferential ly bind to 
the act ive site of TS with a covalent bond, significant ly decreasing dTMP 
synthesIs caLJslng th e cells to become depleted of their only source of de 
novo thymidine, arid resLJlting irl a deoxynucleotide (dNTP) pool imbalance 
(Santi et 81. 1974). This thymine-deprived state has been associated with 
DNA fragmel1lation (CLJrlin et al. 1991) . It the ce lls are unable to salvage 
thymidine, the subseqLJent dNTP pool imbalance (particularly the adenine to 
thymidine (dATP:dTIP) ratio (Houghtoo et al. 1995) will s ignal an 
endonLJclease which wou ld produce direct DNA dOLJble strand cuts , disrupting 
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DNA synthesis and ultimately resulting in cell death. It has also been 
hypothesised that the stability of duplex DNA and resulting DNA double-
strand breaks are affected in a sequence specific manner (Yoshioka et al. 
1987; Sahasrabudhe et al. 1995). 
uracil 5-tluorouracil 
Figure 1.4.1 C: The structure of a uracil nucleotide compared 
to its uracil analogue, 5-FU (Grem, 2000) 
In a thymine-deprived state, because of substantially more dUMP in the cell, 
the levels of deoxyuridinediphosphate and deoxyuridinetriphosphate increase, 
and these ribonucleotides, as well as other unconventional bases (including 
FdUTP), are misincorporated into the growing DNA strand. Subsequent 
recognition and removal of the erroneous bases from the DNA by the base-
excision repair enzyme, uracil-DNA glycosylase (UDG), would leave an 
apyrimidinic site. Once this site is targeted for repair, another futile round of 
dUTP reincorporation would take place in the absence of dTTP which would 
eventually also contribute to the abovementioned DNA strand breakage 
(Ingraham et al. 1982; Sawyer et al. 1984; Curtin et al. 1991; Houghton et al. 
1995; Fisher et al. 2007). DNA fragmentation occurs after the addition of 
FdUDP, suggesting that the removal of the bases by UDG is followed by 
endonucleolytic cleavage, and subsequent DNA breaks (Cheng and 
Nakayama 1983; Shuetz et al. 1986). The presence of UDG supports the 
theory that the cytotoxicity of 5-FU could be as a result of the removal of 
mispaired bases, instead of the actual incorporation into DNA (Shuetz et al. 
1986). 
The drug Methotrexate (section 1.3.1 Aii) also substantially contributes to the 
















FU therapy. It essentially mimics the 5-FU mechanism of action, as 
Methotrexate also promotes the erroneous incorporation of uracil into DNA 
(Goulian et al. 1980b). 
1.4.2 Personalised 5-FU treatment 
i) Clinical toxicity of 5-FU 
The toxic effects of 5-FU treatment are extensive and varied. 
Understandably, and because replicating DNA and cell division are retarded, 
rapidly proliferating tissues, such as the bone marrow and gastrointestinal 
tract (GIT) are affected quite severely. Ulceration of the epithelial lining of the 
GIT causes symptomatic manifestations such as mucositis, gastritis, colitis, 
diarrhea, and nausea or vomiting. Blood-related side effects such as 
granulocytopenia, minor thrombocytopenia and anaemia are frequently 
described. Photosensitivity, alopecia (hair loss), and discoloration of veins 
are some dermatological toxicities that have been reported. Ocular toxicities 
include conjunctivitis, whilst hepatic toxicity is infrequently described. 
Neurological-related toxicities are sporadic, but characterised by cerebellar 
ataxia (www.PharmGKB.org; Grem 2000). 
ii) Thymidylate synthase (TYMS) 
As previously mentioned, the 5-FU metabolite, FdUMP, interacts with the 
enzyme TS (Santi et al. 1974) which is responsible for the conversion of 
dUMP to dTMP. Thus it is safe to assume that polymorph isms in the TYMS 
gene might influ nce the efficacy of this interaction. The best described 
polymorphism in TYMS was first discovered by Horie and colleagues (1995). 
A variable number of tandem repeats (VNTR) in the 5' untranslated region 
(UTR) is thought to predict the effectiveness of 5-FU therapy (Figure 1.4.2A). 
Two or three tandem copies of the repeat (designated 2R/2R or 3R/3R 
respectively), or the heterozygous combination genotype (2R/3R), were most 
commonly found in populations, until Marsh et al. (1999 and 2000) published 
studies on ethnic variation, proposing up to nine repeats in certain African and 
Asian populations. These repeats, situated in the TYMS promoter, act as an 
enhancer and it has been shown that an increased number of the 28bp repeat 













to a 2.6 fold increase in expression compared to the 2R (Kawakami et al. 
1995; Kawakami et al. 1999). Later a G>C SNP was identified within the 
second 28bp repeat, located in the 12th nucleotide (Figure 1.4.2A). This 
common SNP abolishes the ability of the repeat to act as an enhancer. Thus 
the 3R allele will only show increased expression relative to the 2R allele of 
the VNTR if this particular SNP is present (Kawakami and Watanabe 2003; 
Mandola et al. 2003). It is evident from many studies that this variant could 
explain inter-individual differences in response to 5-FU. Pullerkat et al. (2001) 
showed that individuals who were homozygous for the double tandem repeat 
(2R12R), had a better response to the chemotherapy than their 3R13R 
counterparts. 
A 6-bp deletion in TYMS mRNA has been observed at bp 1494 in the 3'UTR 
(NM_0001 071, Figure 1.4.2), and shown to have a prevalence of 0.29 in the 
Caucasian population (Ulrich et al. 2000). Dotor et al. (2006) showed a 
correlation between this variant and well-differentiated tumours, and proposed 
that the deletion is protective insofar as no deaths were observed in a 
homozygous deletion (6-/6-) group. Although the function of this deletion 
remains unknown, it has been speculated that the 3'UTR is rich in microRNA 
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Figure 1.4.2: Most common variants in TYMS associated with enzyme 
activity. A: a 28-bp 5'UTR VNTR; B: G>C SNP in 2nd repeat of VNTR; 

















iii) Dihydropyrimidine dehydrogenase (DPYD) 
It is reported that 5-FU is mainly catabolised in the liver by the enzyme 
dihydropyrimidine dehydrogenase (DPD) (Naguib and el Kouni 1985). This 
enzyme determines the efficacy of the drug since the metabolism of 5-FU is 
limited by the availability of DPD (Tuchman et al. 1985). DPD deficiency 
shows a familial clustering, with autosomal recessive inheritance. A family 
history of pyrimidinemia and pyrimidinuria were often observed in patients 
with decreased haematological DPD activity, who go on to develop severe 
toxicities after 5-FU treatment (Diasio et al. 1988). The first causative 
mutation was discovered by Meinsma et al. (1995). 
Since then, the precise mechanism of action of DPD has been elucidated. 
DPD initiates the catabolism of the pyrimidine bases, uracil and thymine. 
Because 5-FU is a pyrimidine analogue (Figure 1.4.1 C), it is also catabolised 
via this pathway. The primary initial metabolite is dihydrofluorouracill fluoro-
5,6-dihydrouracil, which is rapidly eliminated from the blood plasma (Heggie 
et al. 1987). It is the rate limiting step in the catabolism of the 
fluoropyrimidines. Of the administered dose, 60-90% of the catabolites are 
excreted via the urine, and 2-3% via the biliary system (Heggie et al. 1987). 
Disease-causing mutations in the DPYD gene have contributed to a 
deficiency in DPD (Yokota et al. 1994). A patient presenting with a complete 
lack of DPD activity showed defective mRNA in fibroblasts (Meinsma et al. 
1995). Later, it was observed that as a result of a G>A point mutation in 
intron 14 (IVS14 +1G>A), a 5'-splice donor recognition sequence is abolished, 
and the resulting DPYD mRNA subsequently has a 165 base pair deletion 
leading to a truncated, non-functional protein (Wei et al. 1996). This mutation 
is perceived to be the most prevalent and occurs at a frequency of 0.94% in 
the Caucasian population. The identification of this mutation has helped 
many researchers explain 5-FU toxicity, since nearly 25% of all patients 
presenting with 5-FU-related toxicities, have this particular mutation (Raida et 
al. 2001). There are reports of patients, homozygous for the IVS14 +1 G>A 
mutation, dying after 5-FU administration due to a complete deficiency of DPD 












patients with low DPD activity as a result of a heterozygous splice mutation, 
have reduced capacity to clear 5-FU (Maring et al. 2002). 
Despite its prevalence, the IVS14 +1G>A mutation is not singularly 
responsible for DPD deficiency. Functional expression studies in E. coli 
revealed novel missense mutations such as R29C, a C> T missense mutation 
in exon 2 and 1627 A>G (1543V) in exon 13, which have been shown to lead 
to enzymatically compromised DPD (Vreken et al. 1998). In some instances, 
no sequence variants could be identified to which a deficiency in DPD could 
be attributed, which led researchers to believe that epigenetic promoter 
hypermethylation could be the cause of downregulated DPYD expression. 
For instance, Ezzeldin et al. (2005) studied the promoter of DPYD using a 
novel adaptation of denaturing high performance liquid chromatography and 
found evidence of an association between altered methylation and DPD 
enzyme deficiency in 80% of patients studied. 
1.4.3 Prognostic pharmacogenetic tests 
With the advent of pharmacogenomics, there is a potential to revolutionise 
health care, by providing personalised medicine. Many pharmaceutical 
companies are focussed on harnessing an individual's genetic profile, and 
tailoring a drug treatment regimen according to specific genetic variants to 
predict the outcome of treatment. This is accomplished by studies of how the 
body deals with an administered drug ("pharmacokinetics"), involving its 
absorption, distribution, metabolism and excretion from the body, and how a 
drug exerts its influence upon the body ("pharmacodynamics"). 
A genetic test can have several straightforward purposes; predictive (predicts 
the response to treatment), diagnostic and, more recently, prognostic 
purposes (predicts the outcome of treatment). Prognostic tests provide 
information which will aid in selecting suitable therapeutics and dosages. 
A literature search in the NCBI database, Pubmed, 
http://www.ncbi.nlm.nih.gov/pubmed/.using the phrase "cancer genetic test" 












associated with cancer. However, it is evident that these associated genes or 
variants will not be established as validated commercial clinical tests in the 
near future. Some of the major commercial diagnostic laboratories in the 
United States (US), such as The Laboratory Corporation of America® 
(LabCorp®, Burlington, NC) and Quest Diagnostics (Teterboro, NJ) have 
detailed listings of cancer genetic tests and these tests are available in 
commercial laboratories in the USA and academic institutions. One such test 
assays .for the CD52 marker, an antigen expressed on the surface of 
malignant cells, which determines the eligibility of chronic lymphocytic 
leukemia patients to receive Campath (alemtuzumab), an anti-CD52 drug. 
Another predictive test identifies breast cancer patients who are eligible to 
receive Herceptin. Herceptin is a drug which actively targets the HER-2/neu 
oncogene which is over expressed in HER2-positive breast cancers (HER-2 is 
human epidermal growth factor receptor family 2) (Chin et al. 2006). 
Additionally, the Food and Drug Administration (FDA, USA) has cleared the 
MammaPrint® assay, the first commercialised prognostic test for estrogen 
receptor-positive or -negative breast cancer patients, which predicts whether 
cancer may metastasise (Ross et al. 2008). 
Currently, a few prognostic genetic tests for CRC, predicting treatment 
outcome, are available for use in a clinical setting, and mainly in developed 
countries like the USA. Tests include a chromosome 18q assay which is 
based on the premise that patients with deletions of chromosome 18 are more 
likely to have recurrence of their cancer and hence a shorter disease-free 
survival time (Kirley et al. 2005). A CRC Pharmacogenomic Panel was 
developed by Quest Diagnostics for the management of CRC 
(www.questdiagnostics.com).UnapprovedbytheFDA.this in-house 
laboratory test aims to assay variants in seven genes, which serves to 
evaluate the toxicity response of patients to treatment with 5-FU, Oxaliplatin 
(OX) and Irinotecan (IR). The genes included in the assay are UGT1A1 (for 
IR), TYMS and DPYD (for 5-FU), XRCC1, ERCC1, GSTP1 and XPD (for OX). 
The DPYD IVS14 +1G>A mutation, TYMS 5'UTR and 3'UTR variants, as well 
as a polymorphic TA promoter repeat in UGT1A 1 is examined. Furthermore, 











analysed (Park et al. 2001; Stoehlmacher et al. 2002; Viguier et al. 2005). 
Additionally, this company developed simple mutational analyses of DPYD or 
UGT1A 1 only, which can predict toxicity from the pyrimidine-based agents, 5-
FU and Capecitabine and IR respectively. Their repertoire extends also to a 
vascular endothelial growth factor (VEGF) test to assay response to 
8evicazumab (section 1.3.18) and a test which determines the eligibility of 
CRC patients to receive Cetixumab, an epidermal growth factor receptor 
(EGFR) inhibitor (section 1.3.18). 
Validation of prognostic genetic tests should be required as an antecedent 
before pharmacogenetic testing can be performed. Laboratories can 
commercialise genetic tests via two main regulatory bodies in the USA; The 
FDA and the Clinical Laboratory Improvement Amendments of 1988 (ellA). 
However, many genetic tests, albeit diagnostic or prognostic, are being sold 
directly to the consumer (DTC), without first being substantiated by a health-
care provider to ensure that the test results are not misinterpreted (Katsanis 
et al. 2008). It is not required that laboratories demonstrate clinical validity 
before new genetic tests are deployed, only that the laboratory and test be 
certified under the CLiA. Also, the FDA can only approve manufactured test 
kits from reputable companies and is unable to manage in-house laboratory 
based testing (Katsanis et al. 2008). Recently, the American Medical 
Association has adopted stricter policies on the regulation of DTC genetic 
tests (2008, News Release). 
It is not clear whether a government body exists in SA which monitors genetic 
testing activities, but it is imperative that stricter quality control is exercised, 
globally and nationally, to determine the applicability and limitations to these 
tests. This would ensure that clinical validation occurs, and that the 
information pertaining to a test is accurately conveyed to the public and 
health-care providers. For example, the US laboratory, Quest Diagnostics 
(www.questdiagnostics.com).maintains a strict policy that tests can only be 
ordered through a reputable physician, and test results may only be released 
to the attending physician, and not to the patients themselves. On the other 











results following suit. There should be a mechanism to guarantee that 
genetic tests are properly endorsed by the appropriate authorities before 
being made publically available. 
The question remains whether it is unethical to withhold prognostic testing 
when available, or to provide such tests but without the appropriate control. 
1.5 Aims and Objectives 
The aim of this pilot study was to utilise a range of informative sources and 
molecular techniques, in order to identify the opportunities and challe ges in 
setting up any comprehensive cohort study and to develop a set of 
pharmacogenetic assays pertinent to the use of 5-Fluorouracil (5-FU) in the 
treatment of colorectal cancers. 
In order to accomplish the aim of the study, the following objectives were set: 
a) To identify mechanisms for accessing patient records and biomaterial. 
b) To interrogate and further improve the current patient database in the 
Division of Human Genetics, University of Cape Town (UCT). This would 
serve to establish the first of a network of population-based registries, until 
such time that cancer becomes a notifiable disease. This will facilitate the 
flow of information to the National Cancer Registry in South Africa, alleviating, 
at least to some extent, the disharmony which currently exists in cancer 
reporting. 
c) To perform a critical survey of the referral system at Groote Schuur 
Hospital and UCT, in order to identify means of streamlining data and sample 
capture for the future. 
d) To identify a subject cohort, affected with colorectal cancer from the patient 
registry in the Division of Human Genetics. The cohort will be differentiated 
into individuals who were shown to carry a mismatch repair mutation (Mut+) 
and those that were shown not to (Mut-), and to assess specific disease-
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related features within and between the groups. 
e) To understand the allele frequencies, in patient and control cohorts, of 
potential pharmacovariants in two genes, TYMS and DPYD, known to be 
responsible for interacting with and metabolising 5-FU, which is used in the 












MATERIALS AND METHODS 
2.1 COHORT SELECTION 
2.1.1 Selection of pilot cohort 
The Division of Human Genetics at UCT has performed genetic studies on 
individuals affected with or predisposed to Lynch syndrome type cancers, 
including colorectal cancer, since the late 1980s. Information about these 
individuals is contained in a patient registry located in the Division. 
Individuals affected with cancer are intermittently enlisted primarily from the 
Oncology Department at Groote Schuur Hospital (GSH), a neighbouring 
medical facility, where they receive follow-up. Predisposed individuals 
comprise unaffected family members who are subsequently recruited and 
found to have disease-predisposing mutations. Blood samples are given a 
unique identity number for easy access and to protect the patient's identity. 
The unique identity number is allocated chronologically according to the order 
in which blood was taken and the families identified. The identity number 
starts with a three letter code describing the specific disease (e.g. NPC for 
Non-polyposis Colorectal Cancer), followed by a numerical assignment for 
each member of a family (e.g. 30.1-family 30, member 1, usually the 
proband), and finally the first three letters of the individual's first name (e.g. 
ANN for Anne). 
For the current study, all screening was performed on archived DNA samples 
previously obtained for abovementioned genetic studies. The patient registry 
in the Division contains information on 450 affected individuals, which 
includes probands and their relatives. Of these 450 individuals, 240 have 
been screened comprehensively for mutations in the mismatch repair (MMR) 
genes, MLH1, MSH2 and MSH6. The remaining 210 individuals are affected 
with colorectal cancer, but have yet to be screened for mutations in the MMR 
genes. These 210 unscreened individuals were not included in the current 













database contains the relevant clinico-pathological information and a 
thorough family history of only 144 patients, as well as some follow-up 
information. Additionally, the Division of Human Genetics maintains a 
concurrent database of background control individuals from different ethnic 
backgrounds. Hence 100 control subjects, 50 from Mixed Ancestry and 50 
from Caucasian Ancestry, were admitted to the study. Informed written 
consent was obtained from patients pertaining to the current study (see 
Addendum B for a copy of the form). 
By liaising with the Oncology Department at GSH, the Radiotherapy (RT) 
folders or follow-up records of 80 individuals were obtained with consent from 
patients and the referring physician. A concerted effort was made to populate 
or append the existing registry with phenotypic information inter alia 
pathology, staging of cancers, age at diagnosis, treatment outcomes, survival, 
and prognosis for these 80 individuals, in order to initiate a local population-
based cancer registry. A positive response to therapy was defined as a 5-
year progression-free survival after curative surgery and, if applicable, the 
successful completion of treatment. Recurrence before five years was 
delineated as resistance to therapy (if any) and subsequent relapse. Side-
effects from therapy were noted. Patients or family members were 
periodically contacted in order to obtain updated information relevant to the 
study. 
2.1.2 DNA isolation from peripheral blood lymphocytes and formalin 
fixed paraffin-embedded tumour tissue sections 
Genomic DNA was previously isolated from peripheral blood lymphocytes 
using the PUREGENETM DNA Isolation kit (Gentra Systems). DNA can 
become degraded over time, thus the concentration and purity of each DNA 
sample was investigated using the NanoDrop® ND-1000 (NanoDrop 
Technologies). Quality control was performed by electrophoresis on a 1.5% 
agarose gel (Addendum A) for 25 minutes at 160V. General-purpose sizing 
was carried out using a GeneRuler™ 1 OObp DNA Ladder Plus molecular 
weight marker (0.05I-1g/I-II) (Fermentas Life Sciences, Addendum A). A 
loading buffer containing 40% sucrose and 0.251-11 bromophenol blue (Merck) 
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was used. The DNA was visualised by the nucleic acid stain, ethidium 
bromide (EtBr; 5jJg/ml, SIGMA®). The DNA was viewed using a 
transilluminator (UVITEC). 
The High Pure PCR Template Preparation Kit (Roche, Mannheim, Germany) 
was used to isolate DNA from formalin-fixed paraffin-embedded tissue 
sections. Three tissue sections (5-10jJm thick) were used to attempt to 
amass enough DNA for microsatellite instability testing. The manufacturer's 
protocol was adhered to, except that volumes were downscaled two-fold in 
order to compensate for the small amounts of tissue present. DNA quality 
control was performed as described above. 
2.2 IDENTIFICATION OF MMR-DEFICIENT AND MMR-
PROFICIENT PATIENTS 
2.2.1 Determination of MSI status of affected patients using the 
Bethesda panel of microsatellite markers 
In order to make a clear and detailed comparison between patients with and 
without an intact MMR system, microsatellite instability (MSI) testing was 
attempted on 35 DNA samples of patients who had received chemotherapy. 
The Bethesda panel of recommended microsatellite markers was used to 
assay for MSI (section 1.2.1 iii). The panel comprises two mononucleotide 
markers; BAT25 and BAT26, and three dinucleotide markers; D2S123, 
D17S250 and D5S346. Primer sequences were obtained from Loukola et al. 
(2001). Information pertaining to the markers and their associated primers, 
including the repeat motif of the marker, the primer sequence, fluorescent 
label on the primer, and the size of the amplicon is described in Table 2.2.1 a 
(Addendum B). To analyse MSI, a polymerase chain reaction (PCR) 
experiment was performed on DNA isolated from peripheral blood 
lymphocytes and from formalin fixed paraffin embedded tumour tissue, with 
marker-specific fluorophore-Iabelled primers, and the products genotyped. 
The PCR reaction was performed in a final volume of 10jJl, and contained 1.5-
2.0mM magnesium chloride (MgCI2 ; MerCk), 200jJM deoxynucleotides 
















DNA polymerase (Promega) with 1 x of the appropriate Go Taq buffer and 
0.1 ng/lJl DNA, made up to 10IJI with sterile distilled water (sdH20). 
Optimisation of primer specificity necessitated an increase in MgCI2 
concentration (1.5mM to 2mM) for marker D17S250. Amplification was 
performed on the Thermo Electron Corporation PX2 Thermal Cycler. The 
reaction mix is identical for all five primer pairs and is depicted in Table 2.2.1 b 
(Addendum B), and the correct primer pair is replaced for the various 
microsatellite markers. The cycling conditions are depicted in Table 2.2.1 c 
(Addendum B), and consisted of an initial denaturation step for 5 minutes 
(min) at 95°C, followed by 35 cycles of amplification consisting of: 94°C for 30 
seconds (s), followed by 30s at 50°C, and 72°C for 40s. This is followed by a 
final elongation step of 7min at 72°C. The cycling conditions were identical 
for each primer pair, with the exception that the melting temperature was 
adjusted to 53°C for marker D2S123 to increase the yield. PCR products 
were electrophoresed according to protocol (section 2.1.2) on a 1.5% agarose 
gel for 30min at 160V to determine if amplification was successful. 
In order to determine whether the DNA isolated from tumour tissue displays 
microsatellite instability compared to blood, PCR products from DNA from 
both sources were separated on the basis of size on the ABI Prism® 3100 
DNA Genetic analyser (Applied Biosystems, Foster City, CA) and the raw 
data collected by the ABI Prism® 3100 Data Collection Software. The PCR 
products were diluted by a factor of ten (1/10) and 11J1 of the diluted DNA was 
allotted to its respective well in a Thermo-Fast® 96 Detection Plate. A 
cocktail of Hi-DiTM Formamide (8.51JIlsample; Applied Biosystems) and the 
GeneScan size standard 500 RoxTM (0.41J1/sample; Applied Biosystems) was 
added to the designated wells on the plate. The PCR products were 
denatured at 95°C for 5min before being placed on ice and loaded onto the 
autosampler of the ABI 3100. The results were analysed with GeneMapperTM 
V3.0 software (Applied Biosystems). 
2.2.2 Whole genome amplification of purified genomic DNA 
The majority (80%) of the DNA samples extracted from formalin-fixed paraffin-













failed to amplify despite extensive optimisation. In order to maximise the 
starting template, whole genome amplification was attempted on two samples 
using the REPLI-g® Mini Kit (Quigen, Hilden, Germany) according to the 
manufacturer's protocol, and PCR amplification repeated on the amplified 
products as described in section 2.2.1. 
2.3 DEVELOPMENT OF PHARMACOGENOMIC ASSAYS 
AND SUBJECT PROFILING 
2.3.1 Determination of pharmacorelevant genes and variants 
A list (n=7) of genes involved in 5-FU metabolism was compiled from an 
extensive review of the literature (PubMed; 
http://www.ncbi.nlm.nih.gov/pubmed) and from the PharmGKB database 
(www.pharmgkb.org, Klein ef al. 2001) using the keywords 5-Fluorouracil, 5-
FU toxicity, 5-FU metabolism, 5-FU genes. Two genes were selected 
which had been shown to influence 5-FU toxicity and the 5-FU responder 
phenotype; dihydropyrimidine dehydrogenase (DPYD) and thymidylate 
synthase (TYMS) respectively. Information on variants in both TYMS and 
DPYD that could possibly influence the manifestation of toxic side effects and 
the response to chemotherapy were extracted. Table 2.3.1 contains the 
relevant information for each of the chosen variants; a VNTR in the 5' 
untranslated region (UTR) (rs45445694) and an insertion/deletion (indel) in 
the 3'UTR of TYMS (rs16430), and three single nucleotide polymorphisms 
(SNP) in DPYD (rs3918290, rs1801265, rs1801159). A variant had to comply 
with one or more preset parameters, including a high population 
heterozygosity as published on NCBI (http://www.ncbi.nlm.nih.gov) and/or 
functional studies relating to loss of protein function. 
2.3.2 Gene annotation 
The gene information and sequence of the human TYMS (GeneID: 7298; 
reference sequence: NC_000018.8) and DPYD (GeneID: 1806; reference 
sequence: NC_000001.9) genes were obtained from the NCBI website. 













Table 2.3.1: Information regarding the inclusion criteria pertaining to studied variants in DPYD and TYMS 
Variant Sequence/Nucleotide change Amino acid change Location NCBI Reference 
Heterozygosity 
rs3918290 (SNP) NM_000110.3: c.1905+1 G>A Not detected (ND) Intron 14 ND Meinsma et al. (1995); 
(IVS14+ G>A) Wei et al. (1996) 
rs1801159 (SNP) NM_000110.3: c.1627A>G 1543V Exon 13 0.326 Vreken et al. (1998) 
rs1801265 (SNP) NM_000110.3: c.85T>C R29C Exon 2 0.316 Vreken et al. (1998) 
rs45445694 (VNTR) 
NM_001 071.2: c.43ins28 ND 5'UTR 0.503 Horie et al. (1995) 
rs16430 (deletion) NM_001071.2: c*447-*452deI6 ND 3'UTR 0.49 Ulrich et al. (2000); 


















Ensembl website (http://www.ensembl.org). Approximately 5kb of sequence 
upstream and downstream of each gene was included. The gene annotations 
were based on the version of the genome available on 1 January 2008. 
These sequence files were utilised as input files in a Command prompt script 
to annotate the gene with gene information, marker features and variation 
features. PerlV5 was used as the programming language with the scripts, 
Annotv9 and Annotv9Ev2 courtesy of Dr. G. Rebello (personal 
communication). The output files showed the position of the start and stop 
codon, 5' and 3'UTR, SNP variations (as it appears in dbSNP, with 
accompanying rs numbers) and branch sites. Exonic sequences were in 
upper case and intronic sequences were in lower case. These annotations 
facilitated primer design (see Addenum 8). 
2.3.3 Design of primers to assay relevant variants 
A primer pair, forward and reverse, was designed for each of the variants in 
DPYD and TYMS. Most primers were designed using a selection of 
bioinformatic tools. Firstly, primers were selected using Primer3 (Rozen et al. 
2000), which is freely available on-line at http://frodo.wi.mit.edu/ 
cgi-binlprimer3Iprimer3_www.cgi. and manually modified to optimise 
specificity. Several parameters including a Human Mispriming Library; primer 
size of 18-27 bases; primer melting temperature of 50-60°C; primer GC 
content of 40-60% and a maximum of three consecutive repetitive base pairs 
were specified. The resulting Primer3 primers were subjected to a hairpin 
analysis, self-dim r analysis and a hetero-dimer analysis, using Oligo 
Analyser courtesy of Integrated DNA Technologies (www.idtdna.coml 
analyzerl ApplicationslOligoAnalyzerlDefault. asp x). Pri mer seq uences 
susceptible to these secondary structures were avoided due to the effect they 
may have on the PCR efficacy. The primers were analysed using BLAST 
(www.ncbi.nlm.nih.govIBLASTI) to ascertain whether non-specific 
amplification for the primer pair could be likely elsewhere in the genome 
(Altschul et al. 1990). If Primer3 failed to give satisfactory primers, 
sequences were chosen manually and analysed with the same strict 
parameters. After satisfactory primers were designed, the sequences were 












Oligo 1000M DNA Synthesiser (Beckman Instruments Inc). Table 2.3.3 
(Addendum B) contains the sequence, length, melting temperature and GC 
content of the final primers. The primer sequences in relation to the variants 
are depicted in Addendum B. 
2.3.4 Design and optimisation of a multiplex peR assay 
The amplification of the variants in TYMS, the 5'UTR VNTR (rs45445694) and 
the 3'UTR indel (rs16430), will be discussed separately in sections 2.3.6 and 
2.3.7 respectively. The three SNPs in DPYD (rs3918290, rs1801265 and 
rs1801159) were analysed in a cohort of 179 individuals, derived from the 
larger cohort of 240 individuals, after several lymphocytic DNA samples failed 
the quality checks. 
In order to facilitate the analysis of the three SNPs in DPYD (rs3918290, 
rs1801265 and rs1801159), a multiplex experiment was designed. Before 
amplification of the cohort DNA could occur, the efficiency of the interaction 
between the six primers (three primer pairs, one for each variant) was 
optimised using various methods. Several parameters were altered in order 
to achieve optimal PCR amplification. Primarily, a temperature gradient PCR, 
with primer annealing temperatures increasing in 12 increments was 
performed for each of the separate primer sets individually, using control 
DNA, on a Multigene Thermocycler (Labnet International Inc., WhiteSci). The 
starting temperature was discretionary for each set. Thereafter, the primer 
pairs were pooled in various combinations. To evaluate the success of the 
amplification and establish the optimum annealing temperature of the primers, 
the 12 amplified control DNA samples were electrophoresed according to 
protocol (section 2.1.2) on a 2% agarose gel at 120V for 60 min. Failure to 
obtain distinct and separate bands on the agarose gel signified a subsequent 
optimisation step, which entailed modifying the buffer composition and pH, 
using a PCR Optimisation Kit (Roche Diagnostics). This method comprised 
16 buffers (100mM Tris HCI, 500mM KCI) with varying concentrations of 
MgCI2 and at variable pH. The final optimised PCR setup and cycling 
conditions are depicted in Table 2.3.4a and 2.3.4b (Addendum B). Briefly, the 













template DNA, O.4~M of each primer, 0.5U/~1 of Taq polymerase (Promega), 
1x buffer, 1.5mM MgCI2 (Merck) and 200~M dNTPs (Bioline). Each PCR was 
performed on a Multigene Thermocycler (Labnet Inc.) and comprised an initial 
5min denaturation step at 95°C, followed by 30 cycles of 94°C (1 min), 56°C 
(1 min) and 72°C (80s), with a final 7min extension at 72°C. 
2.3.5 Multiplex genotyping of SNPs (rs3918290, rs1801265, rs1801159) 
in DPYD using the SNaPShoPM reaction 
The method that was selected to perform SNP genotyping was the ABI 
Prism® SNaPShot™ Multiplex Kit (Applied Biosystems). It is a high 
throughput minisequencing-based approach which makes use of an 
unlabelled internal oligonucleotide primer that anneals one base pair 
upstream (5') of the relevant SNP, and is extended by a single fluorochrome-
labelled dideoxynucleotide «F)-ddNTP). The internal primers are designed 
specifically so that the incorporated (F)-ddNTP reflects the corresponding 
SNP (Lindblad-Toh ef al. 2000). The alleles are designated by separating the 
extended products by capillary electrophoresis, and detecting the 
fluorescence. Specific fluorescent dyes are allotted to each individual (F)-
ddNTP, facilitating analysis with GeneMapperTM v3.0 Analysis Software. The 
assignments are shown below in Table 2.3.5a. 
Table 2.3.5a: Dye Assignments of ddNTPs for SNaPShoFM reaction. 
Variant Strand Primer was Alleles Fluorescent Label of Colour for 
designed from expected ddNTP analysis 
rs3918290 positive A dR6G Green 
G dR110 Blue 
rs1801159 negative C dTAMRATM Black 
T dROX™ Red 
rs1801265 positive C dTAMRATM Black 
T dROXTM Red 
The software does not have predefined kit, panel and bin information for 
SNaPShoFM multiplex samples since different primer sets are used by 

















bins needed to be created from reference data. A bin is a base pair range 
and dye colour that defines each allele of a SNP. It is specified by 
boundaries that are user defined. A panel is a set of markers that will be 
analysed. Thus an initial optimisation step (data not shown) allowed the 
primers to be assayed separately and bin sets and panels allocated before 
being pooled and analysed simultaneously. This is an essential step to 
collect the necessary parameters needed to analyse each individual SNP. 
The height of a specific data point was given in terms of relative fluorescent 
units (RFU). A peak height of 150RFU was viewed by the analyst as the cut-
off point, below which a peak was disregarded. Analysis was consistent with 
regards to no-template control samples and cohort samples. When a result 
could not be determined conclusively, the genotyping was repeated to yield 
an unambiguous result. 
The primers for the SNaPShoFM reaction were chosen manually. No 
flexibility is permitted regarding the location of the 3' end of the SNaPShoFM 
primers, therefore, primers could be synthesised from either the positive (+) 
strand or the negative (-) strand. These primers were analysed for possible 
secondary structures (see section 2.3.3). The amplicons obtained from 
primary PCR amplification of DPYD using the external primers (section 2.3.4, 
Table 2.3.3, Addendum B) are used in the SNaPShot™ reaction. BioEdit 
Sequence Alignment Editor (www.mbio.ncsu.eduIBioEditibioedit.html. 
courtesy of Tom Hall; Ibis Therapeutics) was used to prepare a local 
database consisting only of the primary DPYD amplicon, and a local BLAST 
search was subsequently performed to prevent the SNaPShot™ primers from 
inadvertently amplifying another region of the main DPYD amplicon. 
The SNaPShoFM primers were designed with a non-homologous 5' tail (5'-
CM TCM-3' tandem repeat) to produce variably sized extension products 
which differed by 6bp. This enabled sufficient separation by capillary 
electrophoresis. The detail of the SNaPShoFM primers are shown in Table 
2.3.3 (Addendum B). The strand from which each SNaPShoFM primer was 
designed is important to note, since four possible dNTPs may be incorporated 













2.3.5a post-peR purification of DPYD products 
Primary PCR products require a purification step prior to the SNaPShotTM 
reaction in order to remove unused dNTPs and primers that may interfere 
with the subsequent thermal cycling primer-extension reaction. To perform 
the purification, five units of Shrimp Alkaline Phosphatase (SAP) (Promega) 
and one unit of Exo1 (New England BioLabs) were added to 7.451..11 of PCR 
product in a final volume of 101..11. SAP removes the 5' phosphoryl groups 
from nucleotides, and Exo1 degrades the remaining primer sequences. The 
reaction mixture was incubated at 37°C for 60min, followed by a 15min period 
of incubation at 75°C to inactivate the enzymes. 
2.3.5b SNaPShoFM thermal cycling reaction (minisequencing) 
The SNaPShotTM Multiplex Ready Reaction Mix contains AmpliTaq® DNA 
Polymerase, reaction buffer and (F)-ddNTPs. The SNaPShotTM primers were 
tested in a singleplex reaction before multiplex reactions were attempted. 
The amount of water in the reaction was adjusted to accommodate a change 
in primer or template volumes. A master mix was made if several samples 
were analysed Simultaneously. The SNaPShotTM primers were diluted to 
201..lM, and pooled in a 2:2:1 (rs1801265: rs1801159:rs3918290) ratio after 
Significant optimisation, in order to achieve a high signal intensity. The 
minisequencing reaction was carried out in a final volume of 101..11, containing 
41..11 of cleaned-up primary PCR products, 2.51..11 of SNaPShotTM Multiplex 
Ready Reaction Mix and 3.51..11 of pooled primers. Amplification was 
performed for 25 cycles of denaturation at 96°C for 10s, annealing at 50°C for 
5s, and single base extension at 60°C for 30s. 
2.3.5c Post-extension purification treatment 
Post-extension treatment entailed the addition of one unit of SAP to the entire 
SNaPShotTM reaction product and subsequent incubation at 37°C for 60min, 
followed by a 15min deactivating step at 75°C. The SAP removes the 5' 
phosphoryl groups from the unincorporated (F)-ddNTPs. If the SNaPShot™ 
reaction product is left untreated, these (F)-ddNTPs may interfere with the 






















2.3.5d Capillary electrophoresis on ABI Prism® 3100 
The samples were prepared for electrophoresis by mixing 21..11 of the purified 
SNaPShotTM products with 91..11 of Hi-DiTM formamide solution (Applied 
Biosystems) and 0.31..11 of the internal size standard, GeneScan™-120 LlZTM 
(Applied Biosystems) and loaded into a Thermo-Fast® 96 Detection Plate 
(Applied Biosystems). Before electrophoresis on the ABI Prism® 3100 
Genetic Analyser, the double-stranded DNA was denatured for five min at 
95°C on a Touchdown (HYBAID) heat block and thereafter kept on ice for a 
minimum of two min. The raw data was collected using the ABI Prism® 3100 
Data Collection software. 
2.3.5e Verification by cycle sequencing 
Verification of the SNaPShot™ results were performed by cycle sequencing. 
The DPYD PCR products were electrophoresed on a 1 % agarose gel 
according to protocol (section 2.1.2) for 45min at 120V and the resulting 
bands excised from the gel using sterile blades. The DNA was purified using 
the QIAquick® PCR Purification Kit (Quigen) according to the manufacturers 
protocol, and eluted in a final volume of 301..11. The subsequent purified 
products were electrophoresed as per protocol (section 2.1.2) to determine 
integrity and the concentration approximated by comparison with the 
molecular weight marker. The purified PCR products were subjected to 
bidirectional cycle sequencing (both the forward and reverse primer were 
utilised, see Table 2.3.3) using a BigDye ™ Terminator Cycle Sequencing kit, 
version 3.1 (Applied Biosystems, Foster City, CA). The sequencing reaction 
mix and cycling conditions are depicted in Table 2.3.5b and Table 2.3.5c 
(Addendum B). The sequencing reaction was performed in a final volume of 
101..11 and comprised 11..11 Big Dye Terminator Cycle Sequencing Mix (Applied 
Biosystems), 1x Big Dye Sequencing Buffer (Applied Biosystems), 2IJM of the 
appropriate primer, and approximately 50ng/1J1 purified DNA. The cycling 
conditions consisted of an initial denaturation step of 96°C for 5min, followed 
by 25 cycles of 96°C (30s), 50°C (15s) and 72°C (4min). Post cycling, the 
sequencing reaction was purified of primers, dNTPs and salts. This was 
achieved by ethanol precipitation by the addition of 2.51..11 of sodium acetate 
























samples were incubated at -20°C for approximately 60 min to precipitate the 
DNA. Thereafter the products were centrifuged for 10 min at 9,300xg. The 
supernatant was discarded and 301-11 of 70% ethanol added to the pelleted 
DNA. The sample was centrifuged for another 10 min at 9,300xg. After the 
supernatant was discarded, the sample was allowed to air-dry before 
rehydration in 101-11 Hi-DiTM formamide and electrophoresed on an ABI Prism® 
3100 Genetic Analyser and examined using BioEdit Sequence Alignment 
Editor (www.mbio.ncsu.eduIBioEditibioedit.html. courtesy of Tom Hall; Ibis 
Therapeutics) . 
2.3.6 Genotyping of the 5'UTR VNTR (rs45445694) in TYMS 
2.3.6.1 peR amplification 
A group of 179 individuals were genotyped for this variant. This group was 
derived from the larger initial cohort of 240, but a large number of individuals 
were excluded after their DNA samples failed the quality control. In order to 
amplify this variant in patient DNA samples, extensive optimisation was 
required. The variant is located in the 5' promoter region of the TYMS gene, 
which is a GC rich area. Primers, fluorescently labelled with the FAM 
fluorophore, were designed as previously described (section 2.3.3). The 
primer sequences are depicted in Table 2.3.3. Parameters altered to obtain 
optimum PCR amplification included increasing the amount of template DNA 
to 200ng, increasing the final amount of MgCI2 to 3.5mM and extended 
cycling (denaturing, annealing and extension) parameters. Furthermore, a 
Touchdown PCR was performed in order to attempt to increase the product 
yield with conditions as follows: 95°C for 5 min, followed by 7 cycles with 
decreasing annealing temperatures (Ta) of 95°C for 45 seconds, 63°C---+56°C 
for 45 seconds, 72°C for 60 seconds, 30 cycles of 95°C for 45 seconds, 54°C 
for 45 seconds, 72°C for 60 seconds and finally 72°C for 10 min. An attempt 
was made to amplify the VNTR using The FailSafe ™ PCR system buffer 
(Epicentre® Biotechnologies, Madison, WI), that is optimised for amplifying 
GC rich areas, but was unsuccessful. Finally, by addition of 5% glycerol to 
the PCR reaction, amplification was obtained. The final optimised PCR setup 
is as described in section 2.3.4, omitting the MgCI2 and replacing it with 5% 














The PCR cycling conditions are similar to those described in section 2.2.1, 
with the exception of a Ta of 52°C. The conditions are portrayed in Table 
2.3.6b (Addendum 8). 
In order to determine the size of the alleles in a DNA sample and thereby 
derive the number of repeats, genotyping was performed on the A81 Prism® 
3100 Genetic Analyser as described in section 2.2.1. 
2.3.6.2 Verification by cycle sequencing 
Verification of the genotyping results was performed using cycle sequencing 
as described in section 2.3.5e. The sequencing reaction mix and cycling 
conditions were adapted to facilitate the analysis of a GC rich amplicon. 
Primarily, 5% glycerol was added to the reaction mix (Table 2.3.6c, 
Addendum 8) and the cycling conditions adjusted as follows: an initial 98°C 
for 10min, followed by 40 cycles of 98°C (1 min), 55°C (1 min) and 72°C (2min) 
(Table 2.3.6d, Addendum 8). 
2.3.7 Analysis of TYMS 3'UTR insertion/deletion (rs16430) 
2.3.7.1 peR amplification 
The reaction mix and cycling conditions for the amplification of the TYMS 
3'UTR insertion/deletion (rs16430) in 192 patient DNA samples are depicted 
in Table 2.3.7a and 2.3.7b (Addendum 8). A group of 192 individuals were 
genotyped for this variant. This group was derived from the larger initial 
cohort of 240, but a large number of individuals were excluded after their DNA 
samples failed the quality control. The PCR was performed in a final reaction 
volume 251..11, containing 100ng template DNA, O.4I..1M of each primer, 0.5U/1..I1 
of Taq polymerase, 1 x buffer, and 200l..lM dNTPs. Each PCR comprised an 
initial 5min denaturation step at 95°C, followed by 30 cycles of 94°C (1 min), 
54 °c (1 min) and 72°C (80s), with a final 7min extension at 72°C. 
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2.3.7.2 Sizing of fragments by non-denaturing high 
performance liquid chromatography 
In order to effectively size the 6-bp insertion/deletion, non-denaturing high 
performance liquid chromotography (ndHPLC) was performed using the 
Transgenomic WAVE® DNA Fragment Analysis System (Transgenomic Inc, 
USA). Sizing of fragments are possible under non-denaturing conditions and 
the elution behaviour of a fragment is independent of the sequence of the 
DNA. The concept of this method relies on DNA that bind to a positively 
charged stationary column within the system, containing triethylammonium 
acetate ions (TEM), via the negatively charged phosphate ion backbone. 
When an increasing concentration of a mobile phase containing a counter ion, 
such as acetonitrile (thus an increase in the fraction of organic solvent), flows 
through the column, the DNA, and TEM bridging molecule, will be displaced 
off the column in a linear gradient separation manner. The DNA is then 
detected through UV absorption. Fragments will elute in a size dependent 
manner, and since smaller fragments would contain fewer phosphates to bind 
to the column, they will elute first (WAVEMAKERTM Software Manual 2002). 
The 3'UTR PCR products were sized at 50°C. The samples were separated 
within a linear acetonitrile gradient at a flow rate of 1.5mllmin, within a 2%/min 
increase in buffer 8 concentration over 4.5 min. The starting/ending buffer 8 
concentration for the amplicon was 56-70%. The product peaks eluted at 
61%8, between 4 and 5 min. 
Three types of samples are expected after WAVE® analysis; heterozygous 
samples (eluted at approximately 4.4 and 4.8 min), homozygous insertion 
(eluted at approximately 4.8 min) and homozygous deletion samples 
(expected to elute at approximately 4.4 min). The samples could be 
distinguished based on the retention time and peak profile. In some cases 
the distinction was not clear, and subsequent partially-denaturing HPLC was 
performed to verify the results. 
2.3.7.3 Partially denaturing HPLC 
The principle of partially denaturing HPLC is based on the detection of 
















insertion amplicons in an individual that is heterozygous for the deletion 
variant. During heteroduplex formation, two species of DNA (a known 
homozygous sample and a query sample, either heterozygous for the variant 
in question or homozygous for the variant) is mixed under denaturing 
conditions, and allowed to reanneal by cooling. Thereafter two or more 
species of DNA exist in the sample with different thermodynamic properties; 
perfectly matched homoduplex molecules, and mismatched heteroduplex 
molecules. Essentially, the heteroduplex molecules are less stable than 
homoduplex molecules, due to the mismatched DNA (Rudolph et al. 2002). 
The reaction sample containing the mixed DNA is loaded onto an 
autosampler tray and injected into a dHPLC column. The DNA is absorbed 
onto the column (stationary phase) and eluted off the column by means of an 
increase in the concentration of the acetonitrile mobile phase at a constant 
partially denaturing temperature (52-75°C). Under partially denaturing 
conditions, because of their unstable thermodynamic properties and hence 
lower affinity for the column, the heteroduplexes are expected to elute from 
the column earlier than homoduplexes (Xiao and Oefner 2001). 
2.3.7.3a Sample preparation and heteroduplex formation 
For 104 samples, equimolar amounts of the unknown (suspected 
heterozygous) and a known homozygous insertion PCR sample (as 
established during non-denaturing conditions, section 2.3.7.2) is mixed and 
denatured at 95°C for 5min. The samples are allowed to reanneal by slowly 
decreasing the temperature to 25°C at a rate of 0.1 °C/4s. 
2.3.7.3b Temperature and method optimisation 
Prior to deletion detection, the text version of the amplicon was analysed 
using WAVE® software. The software predicts the temperature at which 
heteroduplex detection will occur, based on the melting characteristics of the 
fragment. Certain sequence motifs may affect the melting temperatures of 
the amplicon. SNPs (or deletions) resolve optimally if the helical fraction 
ranges from 70%-85% (thus 70% of the fragment is single stranded at a 
specific temperature). The 3'UTR amplicon had a uniform melting profile 











2,3.7B). Additional ly, the gradient parameters and flow rates were 
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2.3.7.3c WA VE® analysis 
Post heteroduplex formation, the samples were separated within a linear 
acetonitrile gradient at a flow rate of 1.5mllmin, adjusted by means of a -0.2 
time shift, with a 5%/min increase in buffer B concentration over 2.6min. The 
product peaks eluted at 60%B, between 1.5 and 2.5min. The starting/ending 
buffer B was 57-73%. Heteroduplex detection occurred at 55°C. 
If, during the mixing experiment, the unknown sample was a homozygous 
insertion, only homoduplexes would occur after heteroduplexing, and be 
evident on the elution profile as uniform peaks eluting at approximately 2.1 
min. If the unknown sample was heterozygous, hetero- and homoduplexes 
would be present after heteroduplex formation, and the elution profile would 
contain a double peak, eluting at approximately 1.9 and 2.1 min. Similarly, a 
homozygous deletion sample would contain three species after the 
heteroduplex reaction, eluting at approximately 1.7, 1.9 and 2.1 min, resulting 
in a triple peak elution profile. 
2.3.7.4 Verification by cycle sequencing 
Six samples displayed an aberrant elution profile compared to the majority 
profiles, and were subjected to bidirectional cycle sequence analysis as 
described in section 2.3.5e, using both forward and reverse primers. 
Sequencing results were analysed using BioEdit Sequence Alignment Editor 
(www.mbio.ncsu.eduIBioEditlbioedit.html. courtesy of Tom Hall; Ibis 
Therapeutics) . 
2.4 STATISTICAL ANALYSES 
2.4.1 Analysis of age at diagnosis and recurrence-free survival 
Survival curves (based on age at diagnosis of Lynch spectrum type cancer) 
were estimated by the Kaplan-Meier product limit method (Stata; StataCorp 
LP) for 145 and 201 individuals to evaluate the probability that subjects with a 
particular stage (145) or site of cancer (201), respectively, would have an 
earlier age at onset. The individuals included in this analysis are derived from 












analyses failing accurate clinico-pathological and follow-up data. The failure 
event was defined as diagnosis of colorectal cancer. The observation period 
started at birth and ended at the failure event. Some patients were recruited 
and entered into a comprehensive screening programme by the Division, 
following the identification of a disease- causing mutation in a first or second 
degree relative with colorectal cancer. These individuals were thus cancer 
free when entered into the screening programme and some only developed 
cancer after the fact. These patients were censored on the screening date 
and not the date of the failure event since they undergo regular colonoscopies 
and are monitored. This would institute an assessment bias and hence 
tumour progression is altered. The comparison between the curves was 
made by Log-Rank test with a p-value of <0.05 considered as being 
significant. 
Additionally, the Kaplan-Meier product limit method (Stata; StataCorp LP) was 
used to evaluate the survival probability for disease recurrence with or without 
chemotherapeutic intervention for subjects with a particular MMR genotype. 
Patients included into the analysis had received curative surgery and hence 
were disease free at the start of the observation period. Curative surgery was 
defined as a complete removal of the disease. Patients with metastatic 
disease (and receiving palliative chemotherapy) were subsequently excluded 
from the analysis. The failure event was defined as local (reappearance of 
cancer at previously treated site) or systemic/distant (metastases to other 
organs such as liv r, lymphatic system and lungs) recurrence. Total analysis 
time for participants on chemotherapy started from the date of their first 
treatment to either a) the date of first local or distant recurrence; b) last known 
recurrence-free date; or c) date of death if no recurrence was observed. Data 
were censored on either a, b, or c. Total analysis time for participants without 
chemotherapeutic treatment started from the date of curative surgery for 
primary cancer, to either a, b, or c. Kaplan-Meier survival curves were plotted 
and the difference between the curves assessed using the Log-Rank test. p-













2.4.2 DPYD and TYMS haplotype analysis 
In order to obtain phase information for the cohort from the genotyping data, 
haplotype reconstruction was performed using PHASE version 2.1 (v2.1) 
(Stephens et al. 2001; Stephens and Scheet 2005) for both affected and 
control study groups. PHASE v2.1 is a mathematical algorithm that uses 
Bayesian statistics to reconstruct haplotypes from population data and infer 
missing data. Haplotypes of the three bi-allelic DPYD SNPs were constructed 
for each individual from SNaPShoFM genotyping data. Similarly, haplotypes 
of the TYMS 5'UTR VNTR and 3'UTR insertion/deletion were deduced. Some 
genotypes could not be determined experimentally due to poor DNA integrity. 
These missing haplotypes were inferred from known genotype or haplotype 
frequencies using PHASE v2.1 and used in subsequent data analyses. The 
study cohort comprised three population groups; Caucasian (CAU), Mixed 
Ancestry (MA) and Black Ancestry (BKA), and these subjects were analysed 
separately in order to infer population-specific haplotypes. In order to obtain 
reliable results, posterior estimates for the missing phase haplotypes were 
based on 10,000 iterations, with a thinning interval of 1 and a burn-in of 
10,000. Family-based data enabled the use of "known"/specified haplotypes 
which improves performance of the algorithm (Stephens et al. 2001). 
Additionally, the algorithm was run multiple times using random seed 
numbers to determine whether haplotype frequencies would differ significantly 
from one estimation to the next. 
The PHASE program produced several files used for the purpose of this 
study. The primary output document (outputfilename.out) was formatted to 
contain a list of the best haplotype guess for each individual. If a phase was 
difficult to infer, the haplotype was noted in parentheses, and if it was 
uncertain, it was noted by square brackets (Addendum C). Additionally, a 
second file (outputfilename.freq) contained the posterior estimates for the 
sample haplotype frequencies which could also be considered as estimates 
for the population haplotype frequencies (Addendum C). 













significant differences in haplotype frequencies in the case and control 
groups. A control population consisting of 50 CAU and 50 MA individuals had 
previously been genotyped (Honours Project, 2008, Division of Human 
Genetics, unpublished work). The PHASE v2.1 algorithm was applied for 
each population group for both DPYD and TYMS. One hundred permutations 
were performed in order to test the null hypothesis that the case and control 
haplotypes are more similar than different. 
2.4.3 Allele frequencies of pharmacovariants in study populations and 
Hardy-Weinberg equilibrium 
The frequencies of the five variants in DPYD and TYMS were determined for 
each control (CAU and MA) population group, as well as 142 unrelated, 
affected subjects from CAU (28), MA (94) and BKA (20), and compared using 
Pearson's chi-square test (one degree of freedom). In circumstances where 
the expected number of observations (or allele frequencies) were less than 
five, Fisher's Exact test was performed inste d. Both Fisher's Exact and 
Pearson's chi-square require that individuals are unrelated, however some of 
the subjects in the CRC study populations were part of large families, and 
thus only unrelated individuals were included in the analysis. Pearson's 
goodness of fit chi-square test (one degree of freedom) was also performed in 
order to determine whether the observed genotype frequencies differ from 
what is expected for each of the studied variants under Hardy-Weinberg 
Equilibrium. A p-value of 0.05 was regarded as significant, under which the 
null hypothesis, stating no significant difference, was rejected. Bonferroni 
correction was applied for multiple comparisons. 
2.4.4 In silico comparative analysis of allele frequencies of 
pharmacoSNPs in TYMS and DPYD in indigenous African 
populations and Caucasian popUlations. 
2.4.4.1 Construction of variation database 













University of The Witwatersrand assayed genome-wide variation for five 
indigenous African populations (BKAF) (Unpublished Work, 2007). These 
were Sotho/Tswana (STS), Xhosa (XHS), Zulu (ZUL), Khoisan (KHS) and 
Herero (HER). The allele frequencies of 933,684 SNPs were determined for 
126 unrelated individuals (STS:25, XHS:34, ZUL:20, KHS:22, HER:25) using 
the Affymetrix Genome Wide SNP 6.0 Array (Homo Sapiens, Genome 
Assembly: NCB I Build 36, UCSC hg18). This data was compared to the four 
population groups defined in The HapMap project (The International HapMap 
Consortium, 2005). The Affymetrix Array data was stored in a local Biomart 
database with a Martview user interface, which allows a user to compare 
allele frequencies of any SNP assayed by the Affy Array within the five BKAF 
and four HapMap populations. The interface allows SNPs to be queried by 
preset fields such as a dbSNP rs identifier, the associated gene and the 
chromosomal position of the variant. 
2.4.4.2 Frequency estimation of 5-FU pharmacoSNPs in the 
indigenous African populations 
The Affymetrix array assays 933,684 SNPs across the genome. Thus not all 
SNPs in all genes are represented. Therefore, the Affymetrix Array data was 
queried to determine whether any of the pharmacorelevant SNPs featured in 
this study (section 2.3.1), in the 5-FU metabolising gene, DPYD, were also 
genotyped in the 5 BKAF Populations. The respective dbSNP RS identifier 
for the SNPs (rs3918290, rs1801265, rs1801159) were used in the query. 
None of the three SNPs were featured on the array, so no direct allele 
frequency comparisons could be performed. Therefore all SNPs in TYMS and 
DPYD which were assayed using the chip were corroborated against tagging 
SNPs (tSNPs) or local representative SNPs (IrSNPs) associated with the 
three DPYD SNPs on the Ensembl database, as well as with the TYMS VNTR 
(rs45445694) and deletion (rs16430). However, none of the SNPs featured 












2.4.4.3 Comparison of African genotyping data with data 
from The HapMap project 
A comparison of the IrSNPs in TYMS and DPYD was made between the five 
BKAF and The Hapmap European Caucasian populations (CEPH) in order to 
identify SNPs with significantly different allele frequencies that may affect 
treatment outcomes in a population-specific way. 
Once the allele frequencies were obtained for all selected SNPs, a pair wise 
comparison was performed for all the BKAF populations versus the CEPH 
population. The Fisher's Exact Test was used to determine the extent of the 
difference in allele frequencies between these populations. Using a p-value 
cut-off of 0.05, it was determined which SNPs show significant different allele 
frequencies between all the BKAF populations and the CEPH population. 
Thereafter a p-value cut-off of 0.001 was used in order to detect the most 













3.1 COHORT SELECTION 
3.1.1 Selection of pilot cohort 
An attempt was made to obtain follow-up records (RT-folders) of 240 affected 
individuals, currently in the patient registry of the Division of Human 
Genetics, from the Oncology Department at Groote Schuur Hospital (GSH). 
These patients have been comprehensively screened for mutations in the 
mismatch repair system (MMR). The patient registry had been previously 
populated with the phenotypic and clinico-pathological information of these 
patients, inter alia age at diagnosis, pathology, and staging of cancers. The 
RT -folders provided information viz. treatment, treatment outcomes, 5-year 
survival, and long term prognosis. Information was gathered on these 
aspects in order to make a clear and detailed comparison between patients 
with or without an intact MMR system, and to simultaneously initiate a local, 
population based cancer registry. The primary aim was to contribute to the 
understanding of whether the molecular pathological differences between 
these two subgroups influenced response to chemotherapy. 
The registry contained the screening history, clinical, pathological and follow-
up information on 92 individuals with mutations in either one of six MMR 
genes (Mut+), and 148 individuals without a mutation in the MMR genes 
(Mut-), therefore, the patient registry could serve as a valuable resource for 
the study of pharmacogenetics in colorectal cancer, and an entry point from 
whence a local cancer registry could be pioneered which could provide 
incentive to the already existing, yet under reported, National Cancer 
Registry. As shown in Table 3.1.1 a, only 87 Mut+ individuals gave consent 
for their RT-folders to be accessed. RT-folders were available and collected 
for 31% (n = 27/87) of the Mut+ individuals of whom only 13 individuals 











facilities outside Cape Town, with no information available pertaining to 
treatment and treatment outcomes. RT -folders could not be located for 69% 
(n = 60/87) of the Mut+ individuals. The possible reasons for this are 
elaborated on in Chapter 4. Of the 148 Mut- patients, four patients did not 
consent for their folders to be accessed, however, of the remaining 144 
patients, 53 folders had been obtained and 94 (64%) could not be located. 
Of the 53 patients, only 25 received chemotherapy. 
Table 3.1.1 a: Comprehensive summary of the final number of study participants 
# Entire Affected Cohort in 
Division patient registry 
Final recruited Cohort 
# Individuals with Consent 
(n=231 ) 
# RT folders collected 
(n=80) 
# Individuals treated with 5·FU 
(n=38) 
450 
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Comprehensive clinico-pathological information was available from the 
registry for only 144 of the 231 individuals who gave consent, with 80 RT-
folders supporting the information. The distribution of the clinico-pathological 
characteristics of the patient cohort of 144, as obtained from the registry, is 
tabulated in Table 3.1.1 b. For the remaining patients, information was 
discontinuous. Cancers of the distal colon appeared in 66% of Mut- patients, 
whereas 76% of Mut+ patients presented with cancers of the proximal colon. 
It was determined that cancers of the distal colon appeared more frequently 
in Mut- patients, whereas Mut+ patients presented with cancers of the 
proximal colon more often (p<0.001, Fisher's Exact). The Dukes' stage of a 
tumour at diagnosis was not contingent on mutation status (p=0.57; Fisher's 














and duodenal), did not receive any chemotherapeutic treatment In th is 
cohort, chemotherapy was given only for tumours classified as Dukes' stage 
Band C (n=29) Few patients who had received chemotherapy experienced 
local or distant recurrence (n=4), 
T~bl g 3 l1b Cli~ i co -patholog l ca l characte r,, \ic , of 144 m isma tch re pair mc tat lon -
posit iYe and negatiye patients 
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The extent of the toxic side effects of 5-FU treatment in the cohort varied. 
Patients mainly presented with diarrhoea (n=9), nausea (n=12) and/or 
vomiting (n=6) with minor occurrences of hair loss (n=1), cramps (n=1), and 
constipation (n=2). Only one fatality after 5-FU treatment was recorded, 
although the patient was diagnosed with an advanced stage of disease, and 
it is not clear whether the cause of death was due to disease or from a 
severe reaction to the chemotherapy. 
Attendance of the treatment schedules was erratic and non-compliance was 
common. Three patients were active participants in existing clinical trials and 
no information was available about their chemotherapeutic regimen and 
outcomes. Most of the patient cohort received adjuvant ("after surgery") 
chemotherapy, although three patients received palliative treatment for 
metastatic disease. 
The medical records of the majority of the patient cohort could not be traced 
successfully. In an attempt to improve the ascertainment of treatment 
outcome records, substantial remedial actions were taken. Patients, or their 
relatives, for whom treatment records were missing, were contacted 
telephonically in order to determine who their treating physician was and 
what their treatment status or survival status was. The information obtained 
from this exercise was negligible. 
Figure 3.1 describes the organisation of the study cohort as described in 
section 3.1 to 3.4. This figure will be referred to throughout Chapter 3, in 
order to facilitate interpretation of the partitioning of the cohort through the 
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Figure 3.1: Organisation of study cohort facilitating in text referencing 
3.2 IDENTIFICATION OF MMR-DEFICIENT AND MMR-
PROFICIENT PATIENTS 
3.2.1 Evaluation of MSI status of affected patients using the Bethesda 
panel of microsatellite markers 
The original intention was to classify the cohort according to their mismatch 
repair (MMR) status using the Bethesda panel of microsatellite markers 
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(section 1.2.1 iii). In order to make a comparison between patients with or 
without an intact MMR system, microsatellite instability (MSI) was assayed. 
An attempt was made to compare the microsatellite profile of each of the five 
markers in the panel in DNA extracted from peripheral blood lymphocytes 
and tumour tissue. The panel of markers were successfully amplified in DNA 
extracted from peripheral blood for 37 samples. However, the quality of the 
DNA extracted from formalin-fixed paraffin-embedded tissue sections proved 
to be severely compromised. Despite several optimisation methods, the 
Bethesda panel of markers could not be amplified successfully in DNA from 
all tissue sections. Whole genome amplification was attempted, however this 
also proved unsuccessful. Therefore, the mutation status of each individual 
was not based on MSI, but rather on previous comprehensive, reliable MMR 
mutation screening studies. A brief summary of the MMR partitioning 
appears in Table 3.1.1 a. 
3.3 DEVELOPMENT OF PHARMACOGENOMIC ASSAYS 
AND SUBJECT PROFILING 
In order to establish the frequencies of six pharmacorelevant variants in a 
South African (SA) colorectal cancer (CRC) cohort (Cohort 82, Figure 3.1) 
consisting of Black Ancestry (BKA; n==23), Mixed Ancestry (MA; n==169) and 
Caucasian (CAU; n==39) subjects, various methods were used. 
Interrogation of DPYD SNPs 
Three SNPs in DPYD (rs3918290, rs1801265 and rs1801159) were 
analysed. In order to facilitate their analysis, rs3918290, rs1801265, and 
rs1801159 were, after appropriate optimisation, simultaneously amplified and 
interrogated using the SNaPShotTM multiplex genotyping kit. Of the 
attempted 231 samples, only 179 could be accurately ascertained, despite 
repeated efforts to optimise amplification. The subdivision of the observed 
genotypes is presented in Table 3.3a. For rs1801159 (1543V), the 'T1' 
genotype occurred in the majority (76% CAU; 63% MA; 63% BKA) of the 
















+1 G>A) 'GG' genotype occu rred in almost all of the patients (99-100%). The 
'GA' genotype was only detected in a single individual in both the CAU and 
MA population groups No homozygous 'AA' ind ividuals were observed For 
the purpose of this study no BKA control individuals were genotyped for any 
of the DPYD variants 
Table 3.3a: Pa rt,tioning 01 SNP geno types in DPYD in all cohorts 
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Figure 3.3A shows a typical SNaPShotm electropherogram for a compound 
heterozygous individual. Bidirectional sequencing confirmed the specif icity 
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Examination of TYMS variants 
In TYMS, the 28bp 5'UTR VNTR (rs45445694) was in terrogated by 
fluorescent genotyping on the ASI Prism~ 3100 Genetic Analyser Several 
al leles were possible for the VNTR and wem designated 2R 3R and 4R 
based on the nu mber of repeats present (two, three and four, respectively) 
It was evident that a consistent discrepancy in the sizing of the al leles was 
present The expected t,nget amplicon size based on primer locations, were 
369 (two tandem repeats) , 397bp (three tandem repeats) and 425bp (four 
tandem repeats ). However, the 2R, 3R and 4R alleles were reflected as 
fragments of roughly 358. 385 and 413bp respectively. Empirica lly, the 
reason for this discrepancy is suggested to be a function of the GC rich 
sequence properties of the TYMS promoter region, which affects the 
secondary structure of the DNA An example of an electropherogram is 
shown in Figure 3.38 . Of the attempted 231 colorectal cancer samples, only 
192 could be amplified successfully, similarly, 5 contro l samples were unable 
to be amplified. The observed genotype partitions in each of the study 
cohorts appear in Table 3_3b, and it is evident that the most common 
genotypes in all populations were 2R!3R and 3RJ3R. The 4R al lele was 
absent in all populations except MA, [lnd only obsel'./ed heterozygous with 
the 2R and 3R allele_ Verifica tion of the sensitivity of the technique was 
attempted by means of cycle sequencing, but was unsuccessful due to the 
GC ri ch natum of the sequence \Nhich made ana lysis difflcult. 
Table 3 3 b ' Pa rtition ing 01 T YMS 5 ' VN TR geno lypes in sludv coho rls 
Popul . ti on Numbe r of Geno typ es 
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The 6-bp 3'UTR insertion/deletion polymorphism (ind el) (rs16430) was 
successfully inte rrogated by oon-denatu ring and partial ly denaturing high 
performance liquid chromatography (dHPLC) or WAVE'S! analysis in 82 
control individuals of CAU and MA, a;;; wel l as 192 CRC patie nts (BKA-20, 
CAU-29 and MA-143) This method successfully Identified 130 homozygous 
samples containing two insertion alleles (6+J6+), as well as 60 hete rozygous 
individuals wi th both an insertion and deletion allele (6+J6-) , The sampl es 
could be distinguished based on the reten tion time and peak profile, A 
homozygous individual wou ld display a single peak on an elution profile, as 
exemplified in Figure 3.3C 
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Similarly a heterozygous indivkJual would display a double peak profile 
(Figure 3,30). No homozygous deletion iml:viduals (6-16-) could be 
distingu ished from 6+16+ individuals w':th this technique 
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Subsequent partially-denatur ing HPLC was performed for 100 samples to 
verify the results. A control sample with a homozygous 6+16+ genotype was 
hetcroduplexed with each sample to be identified If tile unknown sample 
was homozygous 6+/6+, on ly homoduplexes wou ld be present in the sample. 
and a un iform peak was expected on the elution profil e, If the unidentified 
sample was heterozygous heterD- and homoduplexes wou ld be present. emd 
the elution profile would contain a double peak. Similarly. if the unknown 
sample was homozygous 6-16-, three species would be present in the 
reacbon, ho moduplexes of the inse rtion al lete, heteroduplexes, and 
homoduplexes of the deletion atlele, resu tt ing in a trip le pea k profile. Some 
profites were anomalous, and subjected to bidirectional cycle sequencing to 
resolve the results 
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Cycle sequencing in both fOl"lNard and reverse directions confinned the 
presence of either one or two 6·bp deletion alleles in all query samples Due 
to the nature of the sequence in this region, foor hypothetical 6-bp deletions 
were possible (Table 3.3r.) However, only two, rs16430 and rs 11280056 are 
published and curated These deletions (TTAAAG/- and AAGTTAI-, 
respectively) are separated by a 3-bp difference on the TYMS genomic 
sequence, and were not distinguished by dHPLC analysis Figures 3,3E and 
33F illustrate the aberrant WAVE® elution profiles and subsequent 
sequencing characterisation. The partitions of the Tindel genotypes are 
represented in Table 3.3d, Only two patients were homozygous for the 
TUTR deletion, and both were from the MA population group, as highlighted 
in Table 3.3d, 
Table 3.3~; PLJlati,e 6·hp deletion sequences as determined by Ihe na ture of the 
seQuence in Iho 3'UTR regIOn 01 TYMS 
OBSERVED DEI ET IQN SEQUENCE 
5' GTGGTTATGAACTTT ATAGTTGTTTT A 3' 
HYPOT~ ETICA L 6-00 DElET IONS 
1) dbSN P: '" t6~,'10 Ittooagl_) 
5' G TGG TT Al GAACTTTAAAGTTAT AG T TGT TT TA 3' 
2) dOSN P: ,,11280056 (aagttal-) 
5' G TGG TTAT GAACTTTAAAGTTAT ,lGTTGT TTTA 3' 
3) Pc" ioility A It. " agtJ-l 
5' GTGGTTII,TGII,A CTTl AAAGTT ATAGTTGTTTT A 3' 
4) Po»ibi lily B ia""QW-) 
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MA: Mixed Ancestry 
BKA: Black Ancestry 
Number of individuals 













.:. Only two individuals from MA were identified to carry both deletion alleles. 







3.4.1 Analysis of age at diagnosis of disease and recurrence-free 
survival 
Of the initial cohort of 231 patients, clinico-pathological data on Dukes' 
staging of cancer was available in the registry for a total of 145 patients. 
These patients had presen ed with either Dukes' stage A, B, C or D cancer 
(cohort B, Figure 3.1). Additionally data on the site of the primary tumour 
was available for 201 patients, who had been diagnosed with either proximal 
or distal tumours (cohort B, Figure 3.1). Hence the age at diagnosis of 
disease was compared between patients with a particular stage or site of 
cancer. A cohort of 145 patients with either Dukes' stage A (10), B (51), C 
(75) or D (9) cancer were firstly analysed. Kaplan-Meier survival analysis 
showed that there is no significant difference in the age at diagnosis/cancer-
free survival time from birth, regardless of stage of cancer. In other words, 
patients presenting with Dukes' stage A CRC do not display an earlier or later 















Kaplan-Meier age at diagnosis comparative analysis 
C) 
q 
..... ••••.•••• .1 .... 
').--~ 






I """:,. 1 










"' .....• 1-L· __ I __ 
"";-- -~~ 
' ..... I1._ ,""": 
C) 
10 20 30 40 50 60 70 80 
years 
I 
A ----- B I 
uu.u.u. C - - - 0 
Figure 3.4.1A: Kaplan-Meier age at diagnosis comparison of CRC patients according 
to Dukes staging of cancer (Log-Rank test; p=O.212). X-axis depicts age at diagnosis 
in years. Y-axis depicts proportion of individuals cancer-free at one time. The legends 
A, S, C and D indicate the stage of cancer according to the Dukes stage. A-tumour 
invaded mucosa; S-tumour invaded into but not through muscle layer; C-tumour 
metastasised to local lymph nodes; D-tumour metastasised to distant lymph nodes 
and other organs. 
No significant difference was detected in the age at diagnosis between 
patients with tumours of the proximal colon (includes appendix, caecum, 
ascending colon, hepatic flexure, transverse colon and splenic flexure) 
compared to patients with tumours of the distal colon (includes descending 
colon, sigmoid and rectum). Patients diagnosed with distal tumours, are not 
diagnosed with disease later than patients with proximal tumours (Log-Rank 
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obtained in this analysis is approaching significance, and warrants further 
research in a larger cohort. The difference in age of onset between patients 
with Lynch spectrum extracolonic and colonic tumours could not be 
determined due to small sample sizes which would confer limited statistical 
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Figure 3.4.1 B: Kaplan-Meier age at diagnosis comparison of CRC patients 
according to the site of the tumour (Log-Rank test; p=0.057). Age at diagnosis 
depicted on x-axis in years; proportion of patients surviving at one time depicted on 
y-axis. The legend "proximal" indicated tumours of the ascending colon, hepatic and 
splenic flexure and transverse colon; "distal" indicates tumours of the rectum, 
sigmoid and descending colon. 
As previously mentioned, the medical records of the majority of the patient 
cohort could not be traced successfully. Although some clinico-pathological 
data and intermittent follow-up was recorded in the patient registry, no 
comprehensive follow-up data was available to indicate whether they 
























patients were classified as of "unknown status" and were excluded from the 
analysis. Despite having accessed the medical records of 80 patients (cohort 
83, Figure 3.1), only 58 individuals could be included in the survival analysis 
(cohort C, Figure 3.1). The 21 patients who were excluded had not received 
curative surgery and hence failed to meet the criteria for inclusion. Instead, 
these patients had either received examination under anaesthesia with no 
other action taken, or a biopsy was taken of the tumourls for diagnostic 
purposes only. 
Kaplan-Meier recurrence-free survival analysis was performed in 59 
individuals based on their mutation status in order to ascertain if a patient's 
mutation status determines the time until recurrence of disease. No 
significant difference was observed between Mut+ and Mut- individuals 
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Figure 3.4.1 C: Kaplan-Meier recurrence-free survival curve comparing CRC patients 
with known MMR status. The dotted line indicates patients with mutations in any of 
the MMR genes, whilst the solid line represents patients with no known mutation in 
any of the MMR genes. Recurrence-free time on x-axis in years, proportion of 























Kaplan-Meier recurrence-free survival analysis was performed in 36 MMR 
mutation-negative (Mut-) CRC patients in order to test the null hypothesis 
that there is no significant difference in recurrence-free survival between 
subjects with (n=14), and without (n=22) chemotherapeutic intervention 
(cohort C, Figure 3.1). Analysis with the Log-Rank test showed that there 

















Kaplan-Meier recurrence-free survival analysis 
of MMR mutation negative patients 
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Figure 3.4.10: Kaplan-Meier recurrence-free survival curve of mismatch repair 
mutation negative patients with and without chemotherapeutic intervention (Log-Rank 
test; p=O.717). Recurrence-free survival time in years depicted on x-axis. Proportion 
of patients surviving at one time depicted on y-axis. Patients who had received 
chemotherapy indicated by solid line, patients who did not receive any chemotherapy 

















Additionally, Kaplan-Meier recurrence-free analysis was performed in 22 
MMR mutation-positive (Mut+) CRC patients in order to test the null 
hypothesis that there is no significant difference in recurrence-free survival 
between subjects with (n=9), and without (n=13) chemotherapeutic 
intervention (cohort C, Figure 3.1). The results of a Log-Rank test showed 
that there was no difference (p=O.881) in recurrence-free survival times 









Kaplan-Meier recurrence-free survival analysis 
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Figure 3.4.1 E: Kaplan-Meier recurrence-free survival curve of mismatch repair 
mutation positive patients with and without chemotherapeutic intervention (Log-
Rank test; p=O.881). Recurrence-free survival time in years depicted on x-axis, 
proportion of individuals surviving at one time depicted on y-axis. Patients who had 
received chemotherapy indicated by solid line; patients who had not received 












.3.4.2 DPYD and TYMS haplotype analysis 
DPYD and TYMS haplotypes were inferred in the MA (n=133 [DPYD] and n= 
143 [TYMS]), CAU (n=27) and the BKA (n=16 [DPYDj, n=20 [TYMS]) study 
populations using PHASE, version 2.1 (Stephans et al. 2001; Stephens and 
Scheet 2005). PHASE uses linkage disequilibrium patterns to infer a missing 
locus, based on an observed locus. For DPYD, misSing loci could only be 
inferred for patients with genotype data at one or two out of the three loci. 
Hence 55 individuals from the initial 231 (cohort 82) were excluded for DPYD 
haplotype analysis. Similarly, 41 individuals had to be excluded for TYMS 
haplotype analysis. A number of output files were produced during the 
course of PHASE analysis, and these are presented as supplementary files 
(Addendum C). A summary output file contained a list of the best haplotype 
guess for each individual, which were used in subsequent analyses. Some 
phases and alleles were difficult to infer, and indicated appropriately by the 
software. The software, moreover, estimated the various haplotype 
frequencies for the sample populations, which act as indicators of the greater 
population haplotype frequencies. 
Eight haplotypes were deduced for DPYD in the MA and CAU study 
populations, but only four haplotypes could be inferred in the Black Ancestry 
BKA population. In the BKA study population, all four haplotypes occurred at 
a frequency greater than 5% and no distinguishing haplotype could account 
for the variation in DPYD within the population. Of the eight possible 
haplotypes in MA and CAU, three and four haplotypes, respectively, account 
for the majority of the variation observed and occur at a frequency greater 
than 5%. The haplotype which reportedly confers the greatest risk for toxicity 
(ATC or IVS14+1A-R29C-1543V) appears at very low frequencies in both 
CAU (0.008) and MA (0.0009), and was absent in the BKA group. 
Similarly, four to six haplotypes were inferred for TYMS in the BKA, MA and 
CAU study populations, respectively. The TYMS haplotype which 
purportedly bestows the highest risk for decreased tumoral TS levels, and 















a deletion allole) occur at low freque ncies in each populalion group: BKA 
(00590) Mil (00569) and CAU (00549). TIle es ti mated haplotype 
frequencies for each of the ganes in oach of the study populations are 
presented in a series of figures (Figures 3.4.2A-F), 
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A comparison of the derived haplotype frequencies in TYM$ and DPYO fo r 
each of the study populations is presented in Figures 3.4.2G and 3.4 .2H . 
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Additionally a case-control permutation test was performed in order to test 
the null hypothesis that the case and control haplotypes in the study 
populations are more similar than different. No significant differences were 
observed between the derived DPYD haplotype frequencies of the cases and 
controls in either MA (p=0.95), or CAU (p=0.18). Similarly, the estimated 
TYMS haplotype frequencies for MA and CAU showed no significant 
deviations (p=0.11, p=O.4 respectively). 
3.4.3 Allele frequencies of pharmacovariants in study populations and 
Hardy-Weinberg equilibrium 
DPYDSNPs 
The allele frequencies for each biallelic SNP was estimated in the 100 control 
subjects (CAU and MA) as well as 130 unrelated colorectal cancer (CRC) 
cases. As mentioned in section 2.4.3, both Fisher's Exact and Pearson's chi-
square require that individuals are unrelated, however some of the subjects 
in the eRC study populations were part of large families, and thus only 
unrelated individuals were included in the analysis. Genotypes were 
incomplete for 12 of the individuals as a result of degraded DNA which 
hindered amplification of the variants. Table 3.4.3a outlines the respective 
allelic frequencies. For rs1801159 (1543V), the 'T' allele occurred in the 
majority of the patients. The missense 'e' allele appeared at low frequencies 
in CAU, BKA and MA population groups (0.12,0.19 and 0.19 respectively). 
I n contrast, the major allele in both CAU and MA populations for rs 180 1265 
(R2ge) was the mutant 'T' allele. However, the 'T' allele of this SNP was 
infrequently observed in the BKA population, and the frequency differed 
significantly from that observed in MA and CAU (p<0.01, Pearson's Chi2 
test). The IVS14 +1A allele was only detected in the CAU and MA population 
groups at a very low frequency (0.02 and 0.01 respectively). 
There was no appreciable divergence in allele frequencies between the CRe 
cohort and control individuals, for both MA and CAU population groups, for 
the R29C variation (p=0.77 and 0.73 respectively, Pearson's Chi2). The 
















Pearson's Chi2). No difference in allele frequencies were observed for the 
IVS14+1G>A mutation between each of the populations (p>0.05, Fisher's 
Exact) as well as the control and CRC patient cohort in the MA (p=0.63, 
Fisher's Exact) and CAU population groups (0.35, Fisher's Exact). The allele 
frequencies for BKA control individuals were not established. 
Table 3.4.3a: Observed allele frequencies of DPYD SNPs in Caucasian, Caucasian 
control, Black Ancestry, Mixed Ancestry and Mixed Ancestry control 
populations 
Caucasian (n=28) 
Mixed Ancestry (n=86) 
Black Ancestry (n=16) 
NO - "not detected" 
N/A - "not applicable" 



































1543V 0.12 0.24 
15431 0.88 0.76 
R29R 0.28 0.23 
R29C 0.72 0.77 
0.98 
Abolished splice site 0.02 NO 
1543V 0.19 0.2 
15431 0.81 0.8 
R29R 0.37 0.39 
R29C 0.63 0.61 
0.99 

















TYMS 5'UTR VNTR 
Several alleles are possible for this variant. The frequency distribution in all 
populations is presented in Table 3.4.3b. The majority of the patients in all 
ethnic groups carried the 2R and 3R allele. The 4R allele was not identified 
in any population other than MA and heterozygous with the 2R allele. The 
observed frequency of the 4R allele in the MA population is 1.0%. Allele 
frequencies were established for 140 out of 142 individuals. The genotypes 
of two individuals were undefined due to poor DNA quality, and hence 
excluded from the analysis. 
Table 3.4.3b: Observed TYMS 5'UTR VNTR allele frequency in Caucasian, 
Caucasian control, Black Ancestry, Mixed Ancestry and Mixed 
Ancestry control populations 
Population Number of individuals Allele Frequency 
in population group 2R 3R 4R 
Caucasian 27 46,3% 53,7% NO 
Caucasian control 47 41,5% 58,5% NO 
Mixed Ancestry 93 33,9% 65,1% 1,0% 
Mixed Ancestry control 48 31,25% 66,6% 3,125% 
Black Ancestry 20 35% 65% NO 
NO - "not detected" 
2R - Two tandem repeats; 3R - Three tandem repeats; 4R - Four tandem repeats 
TYMS 3'lndel 
Table 3.4.3c shows the frequency distribution of the alleles for the 3'indel in 
each of the study and control populations. The frequency of the insertion 
allele (6+) was 0.85, 0.82 and 0.82 in the CAU, MA and BKA patients 
respectively. The deletion allele was in the minority and only two patients of 
MA were homozygous. There was no significant difference in allele 
frequencies between populations (p>0.05, Pearson's Chi2), nor between 
control and CRC patients from the CAU population (p=0.15, Pearson's Chi2). 
However, within the MA population group, a trend towards a significant 












and the CRC population (p=0.056, Pearson's Chi2). The frequency of the 
3'UTR indel could not be established in BKA control populations. 
Table 3.4.3C: Observed TYMS 3'UTR deletion in Caucasian, Caucasian control, 
Black Ancestry, Mixed Ancestry and Mixed Ancestry control 
populations 
Caucasian (n=27) 
Mixed Ancestry (n=93) 
Black Ancestry (n=20) 
6+ - insertion allele; 6- - deletion allele 
N/A - "not applicable" 
















No significant difference in genotype frequencies were discovered between 
observed and expected values under Hardy-Weinberg equilibrium for two of 
the SNPs analysed in DPYD, SNP rs1801159 (1543V) and rs1801265 (R29C) 
for CAU, MA and BKA individuals (p>0.05; Pearson's Chi2; Table 3.4.3d). 
SNP rs3918290 (IVS14 +1G>A) was in Hardy-Weinberg equilibrium for only 
CAU and MA individuals, but deviated for BKA patients. Even after 
Bonferroni correction (p<0.125), the deviation was still significant. 
The 3'UTR TYMS indel (rs16430) did not depart from Hardy-Weinberg 
equilibrium (p<0.05, Pearson's Chi2) in the MA population, but deviated in the 
CAU group (p=0.03, Pearson's Chi2). In 100 control individuals of CAU and 
MA, the IVS14 +1G>A SNP showed significant divergence (p<0.05, 
Pearson's Chi2) in both population groups, even after Bonferroni adjustments 
were made. The 3' indel showed a similar departure from Hardy-Weinberg 













Table 3.4.3d: p-values calculated for each variant in DPYD and TYMS to test for 










TYMS rs16430, ' 
',3'lndel 
CAU: Caucasian 
MA: Mixed Ancestry 
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3.4.4 In silico comparative analysis of allele frequencies of 
pharmacoSNPs in the drug metabolising genes TYMS and DPYD 
in indigenous African populations and Caucasian populations. 
Using Fisher's Exact Test, the allele frequencies of 298 SNPs in the 
pharmacogenes TYMS and DPYD were compared between indigenous Black 
African populations (BKAF), and The HapMap European Caucasian 
population group (CEPH), to calculate the significance of the difference 
between all possible population pairings (data available as supplementary 
data, Addendum C). When a particular SNP is compared between two 
populations, the p-value cut-off of 0.05 gives an indication of whether the 
difference in allele frequencies between the given populations are significant. 
Table 3.4.4 summarises the number of SNPs that were consistently 
significantly different between every one of the five BKAF and the CEPH 
population. As evidenced by the data, there is more variation harboured in 
DPYD than in TYMS in the BKAF populations. The allele frequencies of a 
single SNP in TYMS was significantly different between the BKAF and CEPH 
populations. SNP rs2612095 is an intronic variation, located between the 
pharmacovariants of interest, rs16430 and rs45445694 studied in section 
2.3.1 (Figure 3.4.4A). 
The variation contained in DPYD was more extensive (Figure 3.4.4B). A total 
of 89 SNPs showed a significant difference in allele frequencies (p<0.05) and 
40 SNPs registered a more substantial difference (p<0.001), as indicated in 
Table 3.4.4. According to Ensembl, all of the SNPs are located in intronic 
regions, a d their functions are unknown. Moreover, these SNPs do not tag 
any of the variants that were studied in the South African CAU, BKA and MA 













Table 3.4.4: Extent of variation harboured in DPYD and TYMS in indigenous African (BKAF) populations 
Gene Chromosome Gene Total number of Number of SNPs differing significantly between BKAF Number of SNPs 
Size SNPs in gene and HapMap CEU (% of total) compared (%) 
<0.05 <0.001 
DPYD 1 2613 89 (3.4%) 40 (1.53%) 280 (10.7%) 
TYMS 18 235 1 (0.42%) 1 (0.42%) 18 (7.66%) 
Variant of Interest + + 
p<O.OOI: + 
p<O.05: + 
TYMS (Chr 18): I I I I II I 
O'l ('Ij I' r-I Lf) N 
r-I O'l lO oq- r-I O'l 
lO I' O'l r-I (Y) oq-
I' co O'l r-I N (Y) 
N (Y) oq- lO ...... co 
lO lO lO lO lO lO 
Figure 3.4.4A: Graphic illustration ofthe position ofthe variants of interestin TYMS (rs16430, rs45445694) and the SNPs which have significantly different 
allele frequencies (p<0.05, p<0.001) between the indigenous African populations and The HapMap Caucasian population group. The positions of the 
variants are indicated by +, and their base-pair position on chromosome 18 is shown on the X-axis. The black, shaded horizontal line represents the 
TYMS gene, and the seven vertical bars indicates the seven exons in TYMS. 
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Variant of Interest + + + 
p<O.OOl: * + -H- +-HH- + + +ff- + -1+ + + + 11111111 
p<O.05: ....... ........ + IIIIIII11 1111111111 -1+ + + IIII + + -if- 111111 II -1-1*+ 
DPYD (Chr 1): I I I I II I I II 11111 I I 
co 0 N o::t 1.0 .....t 
m ...... o::t r-f co 1.0 
0 o::t co N Lf) (j) 
m 0 .....t (Y') o::t LO 
(Y') m o::t (j) o::t (j) 
0 N LO ,.... 0 N ...... ...... ..... ..... co co 
m (j) m (j) m (j) 
Figure 3.4.48: Graphic illustration of the position of each of the variants of interest (rs3918290, rs1801265, rs1801159) in DPYD and the SNPs which 
show a significant difference (p<O.05; p<O.001) in allele frequencies between the indigenous African populations and The HapMap Caucasian population 
group. The positions of the SNPs are indicated by +, and their base-pair positions on Chromosome 1 are shown on the X-axis. The black, shaded 
horizontal line indicates the position of the DPYD gene on chromosome 1, and the vertical bars represents the exons. 
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The Division of Human Genetics at The University of Cape Town (UCT) has 
performed genetic studies on individuals affected with colorectal cancer, 
since the late 1980s. Currently, demographic, clinical and follow-up data, 
and biological material is archived for 450 probands, and their relatives, who 
are either affected, or at risk for disease (comprising a total of approximately 
1800 subjects). The information about these individuals is contained in a 
computerised patient registry located in the Division. 
In order to correlate disease and clinical outcomes with genetic data (Le. to 
do with the primary predisposing mutation, and/or variants influencing 
chemotherapeutic outcomes) methods/protocols for accessing patient 
records and biomaterial, and the establishment of molecular genetic assays 
was required. Several academic and clinical units are responsible for 
managing each of the aspects of patient care, with their respective 
peculiarities, including challenges and shortcomings. This required a critical 
survey of the referral system at Groote Schuur Hospital and UCT, in order to 
identify flaws, suggest solutions and, where possible, to rectify the problems. 
The present pilot study, which compared a range of features between 
cancers due to defects in Mismatch Repair (MMR) genes (Mut+), and those 
that were not due to MMR defects (Mut-), identified the opportunities and 
challenges for setting up such studies. 
It was determined that cancers of the distal colon appeared more frequently 
in Mut- patients, whereas Mut+ patients presented with cancers of the 
proximal colon more often (p<0.001, Fisher's Exact). This observation is in 
line with international literature regarding a predominance of proximal 
tumours in Lynch syndrome when compared to sporadic CRC (Lynch et al. 
1993). Since the majority of the cohort entering the research registry are 











there was no attempt made at deducing whether a greater proportion of 
younger individuals with eRe are likely to have mutations in the MMR genes. 
The Dukes' stage of a tumour at diagnosis was not contingent on mutation 
status (p=0.57; Fisher's Exact). 
However, this work has also shown that there is a disparity in terms of the 
amount and quality of information pertinent to patients, at each point of care, 
ultimately meaning that patients may not benefit from the potential of 'genetic 
studies/testing', in the current setting, if and when such genetic information is 
shown to be of consequence and value. 
DNA and diagnostic information (Le. diagnosis with eRe) was available on 
each of the 240 subjects in the registry, and for whom mutation analysis was 
carried out. The substantial attrition of subjects between diagnosis and 
surgery for eRe, to treatment with e.g. 5-FU, is partially explained by the fact 
that only a proportion of individuals diagnosed with disease, actually end up 
being further treated with chemotherapy. Even for individuals, who might 
have been treated with chemotherapy, in order to assemble the information 
pertaining to treatment and outcomes, each individual patient had to be 
actively consented, before their 'treatment-folder' could be physically 
interrogated. The ultimate smaller cohort of Mut+ and Mut- individuals who 
were compared with regard to 5-FU treatment and outcomes reflected 
individuals for whom there was reliable information available from admission, 
through surgery and pathology, and ultimately for their oncological 
chemotherapeutic treatment and follow-up. 
In order to capture the data for future studies, an empirical form was drawn 
up onto which the relevant data, regarding treatment modalities and 
outcomes, could be entered. The data on the form was to be captured onto 
the patient database, and would negate the need for arduous paperwork for 














This study successfully improved the current patient database by adding very 
relevant fields pertinent to treatment and outcomes (where patient 
information was accessible). Hence, despite an attrition in information, 
between original patient admission to eventual discharge and follow-up, this 
project ultimately assisted in improving the process of data capturing in the 
Division. So, currently, when a newly-recruited patient enters the 
research/screening programme of the Division, not only is a research blood 
sample collected, but an extensive clinico-pathological history is required, 
and information from the patient's radiotherapy (RT)-folder, if the patient has 
received additional chemotherapeutic treatment, is captured on the database. 
A research assistant has been appointed to actively retrieve new and/or 
outstanding RT-folders from Groote Schuur Hospital and the relevant 
pathology, treatment schedules and treatment outcomes are being entered 
into the database and monitored on a regular basis. This will facilitate more 
comprehensive studies on this valuable cohort in future 
The completion of the sequencing of the Human Genome has paved the way 
for individualising cancer treatment. Several enzyme systems are 
responsible for metabolising chemotherapeutic agents, and it is assumed that 
variations in the genes encoding these enzymes might influence response to 
treatment. Toxicity from, and resistance to, chemotherapy could be 
explained by differential expression of metabolising genes, and genetic 
profiles of patients can potentially aid in discovering effective treatment 
options (Stoelmacher et al. 2002). 
Oncologists in South Africa (SA) do not use mutation status to guide therapy. 
However, there are several prognostic genetic tests currently available in the 
USA, which show promise in changing the way drugs are prescribed. These 
tests are limited in as much as they are developed to analyse polymorphisms 
identified in populations outside of SA. In order for hospitals in SA to 
adequately utilise these tests, the frequency of the variant alleles in 
populations in SA would have to be determined, and thus, whether these 













another aspect of this pilot study was formulated to develop pharmacogenetic 
assays which could be applied in future large-scale studies, to determine 
whether variants in drug-metabolising genes determine the efficacy of 5-FU 
in different populations in SA. In this regard, this project established (i) a 
range of pharmacogenetic tests pertinent to treatment with 5-FU, and (ii) the 
frequencies of polymorph isms in the genes known to influence 5-FU toxicity 
and metabolism in the subject population. 
Although a substantial subject cohort was interrogated for the purpose of 
establishing population frequencies of pharmacogenetic alleles in the 
respective genes, a relatively small proportion of the patients entering the 
system for genetic studies were ultimately triaged for such studies, as 
explained previously. This cohort reflected individuals for whom there was 
reliable information available from admission, through surgery and pathology, 
and ultimately for their oncological chemotherapeutic treatment and follow-
up. The population and patient pilot cohort were studied at five variants 
within the 5-FU pharmaco-relevant genes, thymidy/ate synthase (TYMS) and 
dihydropyrimidine dehydrogenase (DPYD). None of the abovementioned 
polymorph isms have previously been screened in a diverse population such 
as in SA. 
i) Dihydropyrimidine dehydrogenase gene (DPYD) 
The correlation between genotype and phenotype are still lacking for the 
majority of known DPYD mutations, and these may only be common 
polymorph isms which do not influence enzymatic activity. However, some 
mutations are functional and result in an inactive protein. The current data 
reports the frequency of three SNPs in 179 SA Caucasian (CAU), Black 
(BKA) and Mixed Ancestry (MA) CRC patients (of the original cohort of 240 
patients), as well as in 100 control CAU and MA subjects from the 
background population. The inability to reliably genotype the remaining 61 
patients for all three polymorph isms in DPYD may be due to factors such as 












A G>A point mutation in intron 14 (IVS14 +1G>A), abolishes a 5'-splice donor 
recognition sequence, resulting in a non-functional protein (Wei et a/. 1996). 
The IVS14 +1G>A mutation is purportedly the most common cause of protein 
deficiency and normally occurs at a frequency of -1 % in the general German 
CAU population. A large number of German cancer patients (25%) suffering 
from severe 5-FU-related toxicities, have been reported with this mutation 
(Raida et a/. 2001). Similar to other studies, the mutation appeared in the 
present study in the heterozygous state in only 2% of the SA CAU patients, 
and in only 1 % of MA patients. No patients of BKA carried this mutation. 
None of the patients who had received chemotherapy carried this mutation, 
and no excessive side effects were reported. A significant (p<0.05) 
divergence from Hardy-Weinberg equilibrium (HWE) was detected in the 
genotype frequencies for this mutation in the background CAU and MA 
population groups. One would expect these control, outbred populations to 
adhere to HWE, and deviations may indicate errors in the data sets (Salanti 
et a/. 2005). It is hypothesised that the power to detect the deviations might 
have been too low in the current study, due to the relatively small sample 
sizes. 
There are conflicting results about the involvement of the c.85C> T (R29C) 
and c.1627 A>G (1543V) variants with respect to toxic side effects from 5-FU 
treatment. It has been reported that a patient with a homozygous R29C 
mutation suffered from severe toxic side effects after 5-FU therapy (Vreken 
et a/. 1997), and this was substantiated by other studies, further suggesting 
that the presence of the mutant allele leads to an enzymatically inactive 
protein (Vreken et a/. 1998). On the contrary, these mutations have been 
suggested to be common innocent polymorphisms as evidenced by studies 
describing patients homozygous for the R29C mutation, but free from any 
side effects (Collie-Duguid et a/. 2000; Van Kuilenberg et a/. 2000). The 
amino acid positions, 29 and 543, are also reported to be evolutionarily 
unconserved (Mattison et a/. 2002). The relatively high frequency of the 
R29C in patient cohorts is understandable in light of the high incidence of the 



















(0.194 and 0.137 respectively) (Gross et al. 2003). In the current study, 
there was no appreciable difference in allele frequencies between the CRC 
cohort and control individuals for both MA and CAU population groups for 
either the R29C, 1543V and IVS14 +1G>A variants. This is to be expected, 
accepting that these polymorphisms are defined as common in the 
background population, and chosen specifically for their purported role in 5-
FU metabolism. Although no individual difference was noted, the three 
variants, R29C, 1543V and IVS14+1G>A may have a cumulative effect. 
Some ethnic variability was observed in the allele frequencies of the R29C 
variant between the study (affected) BKA, MA and CAU populations. The 
reference "C' allele occurred much more frequently in the BKA population 
than in the CAU or MA groups (p<0.05, Pearson's Chi2). 
ii) Thymidylate synthase gene (TYMS) 
In the present study, 192 CAU, MA and Black patients and 100 controls 
individuals were assayed for the 5'UTR VNTR polymorphism in the gene for 
thymidylate synthase (TS) which converts dUMP to dTMP. Of the initial 
cohort of 240, only 192 DNA samples were of sufficient quality for 
subsequent molecular assays. No novel VNTR alleles were identified in this 
study. Two or three tandem copies of the repeat (designated 2R12R or 
3R13R respectively), or the heterozygous combination genotype (2R/3R) was 
found most often in the current study populations. However, the four-tandem 
repeat (4R) allele was identified in two patients from the MA population and 
found to be heterozygous with the 2R allele at a frequency of 1.0%. Although 
the 4R allele was not found in any other population, it is possible that this 
allele exists in these populations, but at a frequency too low to observe in a 
small scale study. Marsh et al. (2000) identified the 4R allele at a frequency 
of 2-7% in control Black African populations (originating mainly from Kenya 
and Ghana). Thus it was anticipated that this allele would occur more 
frequently in the current BKA study population. However, the BKA study 
sample size was too small to adequately expose the allele, if it does occur in 
the BKA population in SA. It has been suggested that the 4R allele occurs at 











2000). Nevertheless, it was not seen in the SA CAU study cohort. If it does 
occur, it is very likely to be present at a substantially lower frequency 
«0.5%), since it was not evident in the study cohort. It is certainly 
worthwhile pursuing a more accurate estimation of these allele frequencies in 
the various populations in South Africa particularly because of the purported 
role of copy number on drug metabolism and treatment outcome. 
Marsh et a/. (1999 and 2000) proposed up to nine tandem repeats of the 
VNTR in certain African and Asian populations. However, the role of 
ethnicity in response to TS targeted chemotherapy has not yet been 
evaluated. These repeats are enhancer elements and a 2.6 fold increase in 
expression has been reported in individuals harbouring three repeats, 
compared to two repeats (Kawakami et a/. 1995; Kawakami et a/. 1999). 
Over-expression of the TS protein in tumours has been associated with a 
poor prognosis. Lenz et a/. (1998) showed that patients with increased 
tumoral TS levels had disease progression on 5-FU chemotherapy. In 
support of this, Pullerkat et a/. (2001) demonstrated that individuals, who 
were homozygous for the double tandem repeat (2R12R), had a better 
response to the chemotherapy than those harbouring two 3R alleles. 
The 6-bp insertion/deletion (indel) polymorphism in the 3'UTR of TYMS was 
also examined in the 192 subjects mentioned above. Two 6-bp indel 
variations, separated by 3-bp on the TYMS genomic sequence, are currently 
published and curated viz. rs16430 and rs11280056 (TTAAAG/- and 
AAGTT AI-, respectively). Validation by cycle sequencing affirmed that the 
deletion observed in the population could theoretically be either of the 
abovementioned, due to the nature of the sequence in that area, and that 
they could not be distinguished using dHPLC analysis (refer to Table 3.3c). 
Further restriction enzyme analysis will have to be performed to verify which 
3'indel was observed in the current cohort. For the purpose of result 
















The results show that the deletion allele (6-) occurs at a frequency of 0.18, 
0.15 and 0.18 in the BKA (n=7/20), CAU (n=8/27) and MA (n=34/93) 
populations, respectively. This finding is in contrast with other studies which 
have shown the 6- allele to be present at a frequency of 0.41 in American 
CAU populations (n=63) (Mandola et al. 2004). It is evident that some ethnic 
variation of this polymorphism exists and that it is in strong linkage 
disequilibrium with the TYMS VNTR polymorphism (Mandola et al. 2004; 
Dotor et al. 2006). However, no ethnic variability was noted between the 
BKA, CAU and MA study population groups (p>0.05, Pearson's Chi2). 
Studies have shown that patients harbouring two deletion alleles have a four-
fold decrease in TYMS mRNA expression, whereas the heterozygous 
genotype demonstrated intermediate levels of expression (Lecomte et al. 
2004; Mandola et al. 2004). Lenz et al. (1998) proposed that patients with 
decreased tumoral TS levels would respond better to 5-FU, and this was 
corroborated by Dotor et al. (2006) who suggested that the deletion allele is 
protective since no deaths after treatment were observed in their 
homozygous deletion (6-/6-) study group (n=10/129). Although the function 
of this deletion remains unknown, it has been speculated that the 3'UTR is 
rich in microRNA coding sequences, which are known to playa role in mRNA 
stability and translation. In the present study only two patients out of a 
potential cohort of 231, were homozygous for the 6- allele. These patients 
had not undergone any chemotherapeutic treatment. 
An additional dimension to better understand the potential variation in 
pharmacogenes in South African populations, presented itself from results of 
a recent study within the Division of Human Genetics (unpublished work, 
2007). The Affymetrix GenomeWideSNP 6.0 Array 
(http://www.affymetrix.com/products services/arrays/specific/genome wide 
snp6/genome wide snp 6.affx) was used to establish the genetic variation 
harboured in the pharmacogenes of five indigenous Black African population 
groups and to compare the data to that of the four populations in The 














provides information on 906 600 SNPs and 946 000 Copy Number Variants 
(CNVs), per individual sample. The data was used to construct a local 
Biomart database with a Martview user interface, which allows a user to 
compare allele frequencies of a particular SNP within the nine populations. 
By comparatively analysing the allele frequencies of several SNPs in DPYD 
and TYMS, it could be established which SNPs are significantly different and 
could affect treatment outcomes. In retrospect, the data from the Affymetrix 
GenomeWide SNP 6.0 Array should have been included at the outset of the 
study, in order to prioritise the SNPs to be studied in our SA populations. 
However, the data became available for use only at a later stage in the study, 
and was deemed to be valuable in integrating current research with related 
state of the art technology and analysis. 
It was evident that more variation is present in DPYD in the indigenous Black 
African populations, since 40 SNPs showed a significant difference in allele 
frequencies (p<0.001) compared to only a single SNP in TYMS which was 
significantly different between the population groups. DPYD contains 
approximately 2613 published SNPs, of which 280 could be compared using 
the Affymetrix array (-11 %). TYMS harbours as little as 235 SNPs, and 18 
are captured and comparable on the array (-8%). If one takes this into 
consideration, DPYD still has a large number of SNPs (3.4% vs 0.42% in 
TYMS) which have significantly different allele frequencies. This suggests 
that DPYD may be an attractive candidate gene for future studies into the 
pharmacogenetic variation in Africa. 
A significant difference in allele frequencies of a single SNP (rs2612095) in 
TYMS was detected between the indigenous Black African and European 
CAU populations (p<0.001). The SNP is an intronic variation with no 
discernible functional properties. This SNP may, however, still have an effect 













Unfortunately, not all SNPs in DPYD and TYMS were featured on the array, 
and as such the comparison was limited to only a subset of SNPs. Custom-
made arrays provide an opportunity to design experiments which contain 
pharmacorelevant SNPs which are likely to be more applicable to SA 
populations, through biotechnology companies such as Iliumina® and 
AffymetriX®. This would offer one the freedom of choosing appropriate SNPs 
for a specified study, and is highly recommended for future studies into 
pharmacogenomics in SA. 
This present study was successful in its intent to evaluate if colorectal cancer 
(CRC) patients with a defective mismatch repair system (MMR) respond 
differently to the chemotherapeutic agent, 5-FU when compared to their 
MMR-efficient counterparts. For statistical analysis, the current study cohort 
was divided into two groups based on their mismatch repair status; mutation-
positive (Mut+) and -negative (Mut-). Kaplan-Meier analysis of 36 Mut- CRC 
individuals determined that local or distant recurrence of cancer was not a 
function of chemotherapeutic intervention with 5-FU. In 14 patients who had 
treatment with 5-FU, there was no significant difference in recurrence-free 
survival compared to 22 patients without intervention (p=0.643). This is 
contrary to what was expected, given that 5-FU is the main agent used for 
treating CRC, and should increase the survival term of cancer patients (Grem 
2000). However, this research is presented as a pilot study with relatively 
small cohorts, and hence these results should be considered with caution. It 
is important to note that Kaplan-Meier analysis requires large sample sizes 
for adequate statistical power. It is therefore essential that this trend be 
explored further in larger study groups. 
Several studies attempted to elucidate whether the MMR status of a 
colorectal cancer cohort will define a response to 5-FU therapy (Ribic et a/. 
2003; Jover et a/. 2006). These studies distinguished a tumour as MMR-
deficient when a loss of ego MLH1 protein expression or microsatellite 
instability (MSI) occurred. However, no difference in long term response or 














and MMR-deficient (n=23) tumours were detected (Ribic et al. 2003). 
Patients presenting with high MSI (MSI-H) (n=53) tumours, did not benefit 
from 5-FU treatment when compared to individuals with low MSI (MSI-L) 
(n=230) tumours. Conversely, in patients receiving no adjuvant treatment, 
those with MSI-H tumours (n=42) displayed longer overall survival than 
stage-matched sporadic cancer patients with MSI-L tumours or MSI stable 
tumours (n=245) (Jover et al. 2006). In the current study, Kaplan-Meier 
analysis of 22 Mut+ study participants (Le MMR-deficient), nine of whom had 
undergone chemotherapeutic treatment, showed that there is no significant 
difference in recurrence-free survival times between patients with, and 
without 5-FU therapy (p=0.208). Thus, in this cohort, neither MMR-deficient 
patients, nor their MMR-proficient counterparts, seemed to benefit from 5-FU 
therapy. However, as previously discussed, these results should be 
assessed with caution, due to the small size of the study population. 
The age at diagnosis (MD) between patients with a particular stage or site of 
cancer was compared. Kaplan-Meier survival curve analysis exhibited no 
significant difference in the MD (cancer-free survival time from birth) of 
disease, regardless of stage of cancer. In other words, patients were not 
diagnosed with Dukes' stage A CRC at a younger age than, e.g, stage C 
CRC patients. Moreover, patients did not present with tumours of the 
proximal colon (includes appendix, ceacum, ascending colon, hepatic flexure, 
transverse colon and splenic flexure) at an earlier age compared to patients 
with tumours of the distal colon (includes descending colon, sigmoid and 
rectum) (p=0.057). It should be noted that the p-value for this analysis 
approached significance, and therefore warrants further investigation in a 
larger study cohort. 
Now that a formal system is in place, offering Lynch syndrome families 
genetic testing, counselling and clinical surveillance, it is likely that the 
surveillance process would identify Mut+ individuals with disease at an earlier 














Limitations of this study 
As mentioned, this study is considered and presented as a pilot, comparing 
clinoco-pathological features and treatment outcomes between Mut+ and 
Mut- patients and provided an opportunity to identify potential problems and 
suggest solutions for future studies. Due to the retrospective nature of the 
study, a significant proportion of data was missing, despite remedial action, 
and hence the results should be treated with caution. 
The aim was to recruit subjects affected with CRC, who have been treated 
with 5-FU and to relate their subsequent response to their MMR status. Of 
the 240 eligible participants, screened for MMR mutations and being 
managed by the Division of Human Genetics, 38 (13 mutation-positive and 
25 mutation-negative) individuals met the pre-set criteria. These criteria 
included providing consent for access to their treatment data, physical 
hospital folders which were accessible, and treatment with 5-FU. 
The patient database in the Division of Human Genetics is kept current with 
relevant patient information by nurses, divisional staff members and students 
working on the project. Although genotyping data is reliable, patient and 
clinical data may be incomplete, and in some cases, erroneous. In order to 
obtain follow-up (RT) records for the patients, the relevant RT number or 
Groote Schuur Hospital (GSH) folder number were obtained. Despite a fully 
functioning colorectal cancer clinic at GSH, follow-up records and current 
status of the patients were inadequate or missing from the GSH Oncology 
storage facility for a significant proportion of the cohort. In some cases the 
absence of a particular folder could be explained by patients choosing to 
receive follow-up treatment at other hospitals or clinics, nationally, and thus 
inaccessible in the circumscribed time that the study was being conducted. 
Alternatively, some patients were receiving chemotherapy actively at a 
particular time, or receiving follow-up care, and thus their folders were kept 
on hand by the treating physician for the duration of the treatment. Having 
identified that only hard copies of patient-related data is the norm at GSH, a 












solution is to ensure that a liaison person attempts to track the physical files 
relevant to every patient entering the chemotherapy environment, and which 
has, as a result of this study, already been implemented. 
Not all CRC patients at GSH receive chemotherapeutic treatment. Many 
patients undergo a curative resection of the tumour and recuperate without 
the need for 5-FU treatment. Of the 80 patient RT folders that were 
obtained, only 38 individuals (47.5%) had undergone treatment with 5-FU, of 
which three received palliative treatment for metastatic disease, and had to 
be excluded from the analysis. Often, radiotherapy is received instead of 5-
FU. However, the number of individuals receiving radiotherapy and the 
number receiving 5-FU is not mutually exclusive. 
It is clear that the treatment and outcome information that was accessed is 
an under-representation of the whole study cohort. It should be noted that 
remedial actions were attempted throughout the course of the study in order 
to maximise the primary cohort, and include as many CRC-affected patients 
as possible. However, the majority of the patients recruited into this current 
study are obliged to make use of the state-funded medical facilities at GSH. 
They do not have the financial capacity to receive treatment at private 
medical facilities, hence treatment folders are mainly accessed through GSH. 
Telephonic contact was attempted for patients and/or family members for 
whom no records were accessible. Nevertheless, a sizable proportion was 
either unapproachable, non-responsive or did not know their treatment 
details, and the subsequent information obtained was negligible. 
The National Cancer Institute (NCI) supervises the endeavours against 
cancer in the USA. Results of approximately 21 criteria are regularly 
available as free domain on the internet. Only two of these criteria, namely, 
cancer incidence and mortality rates, are captured in SA by the Medical 
Research Council (MRC) and the National Health Laboratory Service (SA 
does not have an USA-NCI equivalent). However, it is recognised that the 












According to the National Cancer Registry (NCR) and the MRC respectively, 
the incidence data and mortality data do not harmonise. The reported 
number of people dying from cancer is purportedly higher than the incidence 
(Albrecht 2006). It is furthermore speculated that the under-reporting of 
cancer cases is more extensive in Black South African population groups 
than in White South African groups. This is due to the disparity in clinical 
services between the different populations groups, as a result of past 
government policies. Therefore it is imperative that the NCR is informed of 
South Africans with unreported cancer diagnoses. Likewise, mortality rates 
in SA have been deemed erroneous by the World Health Organisation 
(Mathers et al. 2007) stating inaccurate death certification. The NCR is in no 
way responsible for these discrepancies, for they are only able to use the 
data that is being provided to them from medical institutions. 
An important aspect of the study of Lynch Syndrome is the technical capacity 
to carry out microsatellite instability analysis. Although the designed markers 
were resolved in lymphocytic DNA, their amplification was problematic in 
paraffinised tumour tissue. It is likely that preservation artefacts, or age of 
stored samples could influence the outcome or attempts to analyse MSI 
status in preserved tumour tissue. In mitigation of the current project, 
however, the study cohort was chosen based on the basis of comprehensive 
germline MMR gene analysis, resulting in subcohorts of Mut+ and Mut-
subjects, respectively. This is considered to be a much more reliable 
indication of Lynch predisposition and cause of cancer (Le. Mut+). There is 
nonetheless, a caveat that at least a small proportion of the tumours in Mut+ 
patients could be a sporadic phenocopy. 
Future prospects 
Several prognostic tests are currently being marketed in the USA for a variety 
of chemotherapeutic agents. Irinotecan (IR) is a topoisomerase I inhibitor 
and a drug frequently used to treat colorectal cancer (CRC) under the trade 
name, Camptosar® (Pfizer Pharmaceuticals Inc., http://www.pfizer.com). 











(UGT1A1) participates in the metabolism of SN-38, the activated form of IR 
(Iyer et a/. 1998). A well-studied polymorphism in UGT1A1, an additional TA 
repeat in the 5' promoter region, has been implicated in the toxic effects of IR 
and is responsible for causing decreased enzymatic activity (Miners et a/. 
2002; Rouits et a/. 2004). In 2005, the FDA added a warning to the 
Camptosar® product insert. It recommends that individuals who are 
homozygous for the TA repeat polymorphism (UGT1A1*28 allele) are at risk 
of developing neutropenia, and should receive lower initial doses of the drug. 
Treating-physicians in the USA can make use of an FDA-approved 
prognostic genetic test offered by companies such as Quest Diagnostics 
(www.questdiagnostics.com) to assay this polymorphism in patients. Since 
this variant is a short tandem repeat, it was not featured on the Affymetrix 
GenomeWideSNP 6.0 Array and hence the allele frequencies could not be 
established in the five indigenous Black SA populations. Therefore future 
studies can be conducted to establish the incidence of the variant in SA to 
determine whether the UGT1A1*28 prognostic test is suitable and widely 
applicable. Beutler et a/. (1998) reported a high prevalence of the additional 
TA repeat in people of African origin, making it a putative marker to study in 
SA. 
A CRC Pharmacogenomic Panel has also recently been developed by Quest 
Diagnostics for the management of CRC. The test is aimed at evaluating the 
toxicity response of patients treated with 5-FU, Oxaliplatin (OX; Eloxatin®) 
and IR. Variants in a panel of seven genes are assayed including UGT1A 1, 
TYMS, XRCC1, ERCC1, GSTP1, XPD and DPYD. As previously mentioned, 
variance in 5-FU and IR metabolism can be attributed to polymorph isms in 
TYMS, DPYD and UGT1A1 respectively (Kawakami et a/. 1995; Wei et a/. 
1996; Ulrich et a/. 2000; Raida et a/. 2001; Rouits et a/. 2004). This test also 
assays the GSTP1-1105V, XPD-K751Q, XRCC1-R399Q and 
ERCC1-T118C SNPs, as indicators of prognosis in order to guide 
chemotherapy selection. These polymorphisms have previously been shown 
through clinical studies to affect how patients respond to OX (Park et a/. 













issues confound the utility of this test in SA. Not only does the haplotype of 
DPYD polymorphisms, which reportedly confers the greatest risk for toxicity 
(ATC or IVS14+1A-R29C-1543V), appear at very low frequencies in both 
CAU (0.008) and MA (0.0009) population groups, but OX is currently not 
used as a chemotherapeutic agent in the public sector, and specifically at 
Groote Schuur Hospital (GSH). Instead, Cisplatin (CIS), another platinum 
derivative is the agent of choice for, inter alia, bladder, cervical and 
oesophageal cancer (Personal communication, Dr Barbara Robertson, 
Department of Oncology, Groote Schuur Hospital). Moreover, the SNPs 
assayed by the CRC Pharmacogenomic Panel were not featured on the 
Affymetrix GenomeWideSNP 6.0 Array and, therefore, the respective allele 
frequencies could not be immediately identified in the five indigenous Black 
SA populations. Therefore, it is doubtful whether this test would be useful in 
the public sector in SA at this point in time. 
It remains, however, that potential studies could determine the difference in 
allele frequencies between SNPs in CIS- and OX-metabolising genes in a SA 
CRC cohort. In so doing, it could possibly be established which of the two 
drugs would be most beneficial and, hence; recommended for use in SA 
hospitals. Of note, are several studies reporting that MMR- deficient cells are 
resistant to CIS but not OX (Aebi et al. 1996; Vaisman et al. 1998; Zdraveski 
et al. 2002). Aebi et al. (1996) carried out experiments on isogenic 
(genetically identical) pairs of cell lines that were either deficient in MLH1 
(HCT116) and MSH2 (HEC59) or proficient in MMR. The authors reported 
that both deficient cell lines were two-fold resistant to the anti-neoplastic 
effects of CIS compared to their counterparts which were expressing MLH1 
and MSH2 (Aebi et al. 1996). Aebi et al. (1997) later independently 
confirmed these findings. This differential sensitivity of MMR-deficient cells 
should be taken into consideration when prescribing platinum compounds to 
HNPCC patients. 
The same applies to another simple mutational analysis of the DPYD gene, 











toxicity from the pyrimidine-based agents, 5-FU and Capecitabine. However, 
the assay has yet to be approved by the FDA, and as such the company 
cannot provide this test to be used as a proven prognostic/diagnostic screen. 
At the moment, the 5-FU package insert contains no information pertaining to 
pharmacogenetic screening for toxic responses. The reason for this is 
because no acceptable, validated test is commercially available yet, despite 
convincing proof that DPYD is involved. 
It would also have to be established whether such a test would be cost 
effective if made available to individuals within the public and private health 
sector of SA. SA is a developing country, with limited resources. However, 
this current study provided valuable insight into several pharmacogenetic 
variants, which could contribute to the development of future SA-specific 













This pilot study was formulated to identify mechanisms for accessing patient 
records and biomaterial, and developing assays and analyses, towards larger 
scale studies on an established CRC cohort. Moreover, a critical survey was 
performed of the referral system at Groote Schuur Hospital and UCT, in order 
to identify means of improving data and sample capture, for more 
comprehensive and meaningful analyses in future. 
This research has laid the foundation for future studies which will aim, 
amongst other things, to determine whether South African (SA) colorectal 
cancer (CRC) patients with a defective mismatch repair system (MMR) 
respond differently to the chemotherapeutic agents when compared to their 
MMR proficient counterparts. In order to perform statistical analysis with 
sufficient power, future patient cohorts will have to be maximised. This would 
very likely entail recruiting individuals not only from Groote Schuur Hospital 
(GSH), but also from other private and state institutions in SA, and obtaining 
complete treatment records. Additionally, implementing a reliable informatics 
system, at every point of patient care and follow-up, to capture patient data at 
GSH, and elsewhere, would facilitate the collection of valuable information for 
research aimed at understanding the heterogeneity of disease, its 
manifestation, targeted treatment, and improved prognosis. 
Cancer surveillance and control in SA is dealt with in a fragmented fashion, 
lacking an optimal infrastructure, and without a definitive policy on cancer 
control. It is therefore advisable that the National Department of Health 
(NDOH) of SA establishes a Cancer Control Programme, which will include 
key role players such as clinical and research institutions, whose main focus 
will be to alleviate these discrepancies (Albrecht 2006). As mentioned 












imperative that the surveillance infrastructure is remedied by changing the 
legislation such that all cancer diagnoses are notifiable to the NCR. In the 
interim, a network of population-based registries needs to be established, 
until such time that cancer becomes a notifiable disease. The research 
conducted in this study contributes substantially to this endeavour. This 
improved patient registry, and the reinforcement of relationships between 
role-players at each point in patient care and management, at GSH and UCT, 
will facilitate the flow of information to the NCR, where it can be evaluated 
(Albrecht 2006). 
In addition, the current study was intended to evaluate whether variants in 5-
FU-metabolising genes can be studied in future to determine the efficacy of 
the drug in different populations in SA. Five variants within the 5-FU 
pharmacorelevant genes, thymidylate synthase (TYMS) and 
dihydropyrimidine dehydrogenase (DPYD) were studied in order to gain 
valuable insight into the frequencies of these five variants in SA, which could 
contribute to the development of SA-specific prognostic tests, which would be 
more affordable and applicable. 
This could serve as valuable groundwork in order to expand 
pharmacogenetic studies of other cancers and chemotherapeutic modalities, 
towards individualised cancer treatment, and improved prognosis. Toxic side 
effects and resistance to chemotherapy could be explained by differential 
expression of metabolising genes, and genetic profiles of patients can 
potentially aid in discovering effective treatment options. Oncologists in SA 
do not use mutation status to guide therapy. There are several prognostic 
genetic tests currently available in the USA, which shows promise in 
changing the way drugs are prescribed. These tests are, however, limited in 
as much they are developed to analyse polymorph isms identified in 
populations outside of SA, emphasising the need to develop larger scale 
pharmacogenetic studies, in sizable cohorts of subjects encompassing the 
various population groups present in this country. More importantly, and as 













integrity of patent-related data from point of admission and diagnosis, 
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General recipes and protocols 
Dilution of primers to a working stock of 20IJM 
ODx 35 
----=Xj..iM 
- nmerx 330 
20j..iM 
Xj..iM x 200 f1l = volume Y 
The Optical Density (00) is a measure of the concentration of primer in the stock 
solution and -nmer specifies the length of the primer. Volume Y is the volume of 
concentrated primer solution that is made up to 2001J1 with sterile distilled water and 
vortexed briefly. 
Tris borate EDTA Buffer (TBE) 
10xTBE buffer: 216g Tris [hydroxymethyl] amino methane (TRIS) (USB); 110g 
boric Acid (Promega) , 14.8g EDTA made up to 2L with distilled water. Dilute to 1 x 
as required. 
Agarose gels (1%,2%,3%) 
1 %: 1 9 of Agarose powder dissolved in a final volume of 100ml 1 xTBE buffer; 
with 51J1 ethidium bromide (5ng/IJI). 
2%: 2g of Agarose powder dissolved in a final volume of 100ml 1 xTBE buffer; 
with 51J1 ethidium bromide (5ng/IJI). 
3%: 3g of Agarose powder dissolved in a final volume of 100ml 1 xTBE buffer; 























DNA Size Standard: 
GeneRuler™ 100bp DNA Ladder Plus (Fermentas International Inc, Canada) 
bp 8gfO.5pg .%. 
3000 28.0 5.5 
2000 28.0 5.5 
1000 28.0 5.6 
1alO 28.0 5.6 
Hl00 80.0 16.0 
900 27.0 5.4 
..... 800 27.0 5.4 
0> 
8 700 27.0 5.4 
ct: BOO 27.0 5.4 ~ 
'" 500 80.0 16.0 i 400 30.0 6.0 
"" 300 30.0 6.0 0 cr:J 
::l alO 30.0 6.0 
~ 






O.5~gllare, 1km length gel, 
1XTBE, 5V!cm, 1h 
Agarose DNA Loading Dye 
0.25% bromophenol blue (0.1259); 40% sucrose (209) made up to a final volume of 
50ml with distilled water. 
123 
 OOb  lad






























Supplementary information to experiments 
Index: 
Consent form for Request of Molecular studies 
Radiation and chemotherapy follow-up record acquisition form 
Table 2.2.1a: Bethesda panel of microsatellite markers 
Table 2.2.1b: Reaction set-up for PCR amplification to determine MSI 
Table 2.2.1 c: General cycling conditions for PCR assay of m icrosatellite 
instability 
Annotation of DPYD with position of primers relevant to variant sequences 








Table 2.3.3: Primer information for analysis of variants within the 131 
pharmacogenes TYMS and DPYD 
Table 2.3.4a: Reaction set-up for multiplex PCR assay of pharm acogenom ic 132 
variants 
Table 2.3.4b: General cycling conditions for multiplex PCR assay of pharmaco- 132 
relevant variants 
Table 2.3.5b: Reaction mix for cycle sequencing of DPYD variants, rs3918290, 132 
rs1801265 and rs1801159 
Table 2.3.5c: Cycling conditions for cycle sequencing of DPYD variants 133 
Table 2.3.6a: Reaction set-up for PCR assay of TYMS VNTR (rs45445694) 133 
Table 2.3.6b: General cycling conditions for PCR assay TYMS VNTR 133 
(rs45445694 ) 
Table 2.3.6c: Reaction set-up for cycle sequencing of TYMS VNTR 134 
(rs45445694 ) 
Table 2.3.6d: Cycling conditions for cycle sequencing of TYMS VNTR 134 
(rs45445694 ) 
Table 2.3.7a: Reaction set-up for amplification of TYMS 3'UTR 134 
insertion/deletion (rs16430) 
Table 2.3.7b: Cycling conditions for amplification of TYMS 3'UTR 














REQUEST FOR MOLEClILAR STUDIES (DNA) 
R_r Ioborllol)' DI._ orS-.. CltfttII .. (R .. l'O.14) 
F.....,..r_llh 5<1_ .. 
1l._ilyol'C ... T ..... 
AtU:ioRMd 
Oboen ... rym5 
Tei'jU21)4{l66l7J t'ltt: (021)_0 
&a. fill ill /Ill tA, itrftm!wtjtm 1JIII1ICJttIrI; 
Sumarne: VAN lIJIlKIIRK 
Blood _d 1>0 _ .. In 2 pi_ fDTA Toboo 
(PuapIc 1Op)'1- 10m} each ..... a yellow •• nel. 
EactI "'1>0 sbollcl b. in...ml !o """ ""'...,.1<1 .. 
cloarly iaIJdIed wilh Iht ~"""'" """ DOe 
Keep blood in fridS- at 4·C .. t,l obI< "' ..... t. "' ...... .,y 
_2W!2I ..... .,.-.. I ..... -... 
NcwFamily: Yes 0 Nu 0 Please nn in Family name/lab Nr: ___________ _ 
Medicalaid: _______________ _ Medicalllid No: _________ _ 
Sex; MO .'0 
Ethnic Origin: nlod< 0 
OllteofBirtb: y"" ____ M-_____ ~. ____ _ 
CoomctA~ _______________ _ 
Tel _______ _ 
--------•.•.. -----.. -.--.. 
E~ ________________________ _ 
ReferrinllllootorlSister: ________________________ _ 
llot!pilalor_ 
Bloods laUD for. Resean:h [] 
Disease Status; AffeclCd [] AtRisk [] 
Bloods taken for: Oiaanostic C 
~StalUS: Aft'ccted C 
Bloods laUD for: Predictive C 
Di_Status: At Risk [] Spouse [] 
Blood, taken fur: POIItTest o 
Forward 111)' predictive test resuhs to: ______ _ 
DNAfftIIIfby. ___________ . 
Fa; 
rel 
Dille ofNm Visit: 
r-----·~·-·-·-·~·----......., 
! I / I 
;,.-~,.-.. "''''--~.~,----,,--...... , .... -.-.,.-...... ,-,-. ..: 
Address: ______ . 
.... NOn: - ,LEASt INSU.T A FAMILY PEDIGREE DIIA\\'1NG ON THE REVERSE OF nns roRM 
CONSENT FOR DNA ANALYSIS AND STORAGE 






genetic material to .. e" tile probability that I I my child' my unborn child 
(DELETE WH!RE NOT APPUCABlE) 
might hIM! inheri1ed a disease-caualng mutation in the gene \'0(; 
I understand that trnI genatlc material \'0( analysis is to be obtained from: 
blood cens I skin sample I other (sp&cify) fDElETE WHERE NOT APPUCABI..E) 
I request that nD portion of the .ample be stored \'0( later use. [J (MARK IF APPUCABlE I 
Q!! 
I request that a portion of the sample be stored indefinitely for (DELETE WHERE NOT APPUCABLE} 
( .) possible re-analysi$ 
C b ) analysls for the benefit of ntembere of my immediate family 
I c I researdl purposes. subject to !he approval of the University of Cape TO'Ml Researdl 
Ethics COmmillee provided \hat any information from such reeardl wHl remain confidential. 
The results of the analysis c;anied out on this .ample of stored bioIogiCaf matet1a1 Will be made known 
to me, via my dOdOI'. in accordance With tile ratevant protocol, if IIIOd when available. 
In addition, I 8U!tlorise that they may be made known to; (l)EUlTE WHERE NOT 
APPLICAlilLE, 
Cal otherdOClors ilMllved in my c;are _________________ _ 
(b) the follOWIng family members: 
o~ __________________________________________________ __ 
t aulhorise I do nat authorise my doc:tor(t) to provide relevant clinical details to the Division of Human 
Geneties. UCT. (l)ELETE WHERE HOT APPUCA8I..E, 
I I1ave been informed that: 
,a) There _ riskl and benefits assoCiated With genetic analysis and storage of biological materiaf and 
these have been explained to me. 
fbI The analysiS proeeclure I. specl!lc to the genetic condition mentioned ab0¥8 and cannot deIlIrmine 
the complete genetic makeup of." iMlviduel. 
Ie) The genetlcs laboratory I, under an obIgaIion to respect medical ccnIkIentIaIlly. 
td, Genetic analylll. may no! be informative \'0(_ families orfamfly members. 
'e) Even WIder the best condiUons, current technology of thl8 type is not perfect and could lead 
to IncolTect m ..... 
(fJ Whem biological material Is used f'or research purposes, there may be no direct benefit to me. 
7. I understand that I may withdraw my consent \'0( any aspect of the abOye alany time without this 
affecting my fUture medical care, 
ALL OF TlIE ABOVE HAS BEEN EXPLAINED 1'0 ME IN A LANGUAGE THAT I UNDERSTAND 
AND MY QUESTIONS ANSWEllED BY: 
SlgnatureC-. __________ _ Date: _L_ 
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RADIATION AND CHEMOTHERAPY FOLLOW-UP RECORD 
NPC NUMBER: ...................................... RT-NUMBER: ................................... . 
1. Follow-up Record 
The most important fact to establish from the follow-up record is to determine whether a patient 
had a recurrence of any cancer since they were admitted to the hospital for their primary colon 
cancer. 
1 . Photocopy the follow-up summary document in the front of the RT -folder. 
2. Briefly go through the detailed notes to establish whether a patient had presented with 
another cancer since their initial admission for the primary cancer 
3. Photocopy all pathology forms that are found in the RT-folder. 
2. Chemotherapy record (please record the following information) 
A. The Primary Site of the cancer ......... '" ................ , .... '" ..... . 
B. The Start date/ First date for chemotherapy ... '" ...... '" ....................... , .. . 
C. The End date for chemotherapy ......................................... . 
D. The patient's: i. Weight in kg ......................................... . 
ii. Height in cm ......................................... . 
iii. Surface area in m2 .••••• '" •••••. '.' •••.•••••••. '" ••.... '" 
E. The drugs prescribed for the patient: Drug 1: ................................ . 
Drug2: ................................ . 
F. The dose ordered in mg: Drug1: ........................... '" .. . 
Drug2: ................................ . 
G. The number of chemotherapy cycles that had been completed for a patient: 
H. If the prescribed cycles were stopped due to complications, please indicate the reason 
for doing so (if listed) 
3. Radiotherapy treatment sheet (please record the following information) 
A. The site that was treated ............. , .................................. . 
B. The start date of radiotherapy treatment.. ................................. . 
C. The end date of the radiotherapy treatment. ...... , .......... '" ...... '" ..... . 
D. The instrumenUmachine that was used for treatment ....... , ............. '" ..... . 
E. SSD ................................................ . 
F. Field size ................................................. . 
G. Norm TD/CD ................................................. . 
H. Dose/Frac ............ '" .................................. . 
I. Number (#) of fractions ................................................ .. 
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Table 2.2.1 a: Bethesda panel of microsatellite markers and associated primers (adapted from Dietmaier et a/. 1997) 
Marker Repeat Motif & Primer name Fluorescent Label OD/ml Concentration (~M) Size Range 
D2S123 Dinucleotide (CA)13TA(CA)1S(T/G A)7 
D2S123 F: 5'AAACAGGATGCCTGCCTTTA 3' FAM 336.1 1782.3 197-227bp 
D2S123 R: 5'GGACTTTCCACCTATGGGAC 3' 499.2 2647.2 
D17S250 Dinucleotide (T A)7 •..... (CA)24 
D17S250 F: 5'GGAAGAATCAAATAGACAAT 3' FAM 388.9 2062.3 140-170bp 
D17S250 R: 5'GCTGGCCATATATATATTTAAACC 3' 506.5 2238.3 
D5S346 Dinucleotide (CA)26 
D5S346 F: 5'ACTCACTCTAGTGATAAATCGGG 3' TET 157.4 758 96-122bp 
D5S346 R: 5'AGCAGATAAGACAAGTATTACTAG 3' 446.9 1887 
BAT25 Mononucleotide TTTT.T.TTTT. (T)7A(T)2S 
BAT25 F: 5'TCGCCTCCAAGAATGTAAGT 3' HEX 264.8 1337 90-125bp 
BAT25 R: 5'TCTGGATTTTAACTATGGCTC 3' 344.8 1741 
BAT26 mononucleotide T s •••• A26 
BAT26 F: 5'TGACTACTTTTGACTTCAGCC 3' FAM 63.2 306 80-120bp 














Table 2.2.1 b: Reaction set-up for PCR amplification to determine MSI 
Reagent Stock 1)( (~I) Final 
Concentration Concentration 
sdHP (SABAX) N/A 5.67 -
Go Taq Buffer (Promega) 5x 2 1x 
MgCI2 50mM 0.4 1.5mM/2.0mM 
dNTPs (Bioline) 5mM 0.5 200IJ M 
Forward Primer 20IJ M 0.25 0.41J M 
Reverse Primer 20IJ M 0.25 O.4IJM 
Go Taq Polymerase (Promega) 5 Units/lJl 0.02 0.1 Units/lJl 
DNA 10ng/IJI 1 0.1ng/lJ l 
Final Volume 10 
Table 2.2.1 c: General cycling conditions for PCR assay of microsatellite instability 
Denaturation 195°C for 5 min 1 cycle 
94°C for 30 s 
Am plification 50°C for 30 s 35 cycles 
72°C for 40 s 
Final Extension 172°C for 7 min 1 cycle 
128 
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Annotation of DPYD with positions of primers 




alia lag eIIIIClllglc~~aagga gacicaalalClilact ~ > ~ > ~ ctltcalcag GACA TT GTGAC AAA TG 
TTT CCCCCAGAATC ATCCGGGGAACCACCTCTGGCCCCATGTATGGCCCTGGA 
CAAAGCTCCTTTCTGAATATTGAGCTCATCAGTGAGAAAACGGCTGCATATTGG 
TGTCAAAGTGTCACTGAACT AAAGGCTGACTT'TCCAGACAA'C 'g 14760021 Icitl 
I dbS N P , :< 391829 a Ita~glglga lilaa r.alclaaa ar. aaga gaallggcalaagllgg 19a aigmaillaaa 
r.alccaattcataggcllataaatattaalgtgtataliliallaaagaatctgccagligclltgctgatgcatagaaagat 
aaaaaaga~~gaaaagctca~gaactc ~l~aaaacr. cac~ ca~lglgaagClllgll~I~aa lgg g lgr.ca igia 
agalggaag aagta tctaca taag cagaaggaagagaaatgaaa tactcaliliallga gttggtttteactgtatgtg 
getggtalitatg~~ggtg~tg~ccliaggaagaaatlgl~~aclala~~lcallilaa~Ial~aacctgaggcagaag 
cagcatalclicctatgaagtcl'atattttlicagtgggaaataalitallaaataaliliaacaetcctataetaaallagte 
~~ cta t etttt~laaaa t etttttlltr.l cllaaag~acc~ lgr.cta ~~ lallgcagl ~aaa lcaggctlg aala laal aga ta 
atalillctclicaatagtctga llag ggtg atccilaa lg'tcattea tttalig tecctateccteccaectcectctecc~ctl 
cClattttttlr.claclr.cllr.IIr.Clclllr.lclclr.lcalr.r.llcCIr.lcllIIcr.ccICCCIr.clcr.lcaallr.lctgtctr.'lllcaaa 
tatacacaacllatttctclltctttcallclltctttcaatgaallgllagtgaatgg aggttgaggtttgag«««<gc 
aatg tgtghgg lila 19 lea 
R29C 
Ig agr.cagglg galcgr.llgagar.caggagllcaagar.cagr. ctgggcaacatggcgaaacctcatctctallaaa 
aatataaaaallagccaggtgtggtagcgtacgcetgtagtcegagctaclIgggag~ctaaggtgggaggalegcc 
Ig agr. ctggaaggcagagg ltgcagtgaar.tgaga llgtaccactg cactccagcctgggtgacaaag tg agaga 
gaccgtgte1caaaataaataaaaalaaaataaaa~taaglltaa~eaaahtgce~~catatitcr.alatalllac~ca 
Ilgllt ~ > ~ > ~~atgclgtctttagAG T A TC CTGG CTTT AAA TC CTC G AAC AC AAACT CAT G 
CAACTCTG'C: (42731) l\li~lldb~ ~p ,.'801265) GTTCCACTTCGGCCAAGAAA T 
T AGACAAG AAACA TTG GAAAAGAAA TC CTGA T AAG AACT G CTT T gtaagtaceactgat 
aeactalltc~tgctgaaaallacetc~ctcc~cac~ttgt~~ggc~a««~~ g~tttt~ca tac~cttag aa~l~ 
aggiallaaag tar. agccg tg a lilla aaaata lillaaa talitaatalit 
1543V 
actgcr.lllgaaa ltaa aaggcr. ata liata tgaalicag ltcactg ctcactgacIII1'tgccaglllllltcaligtaaaca 
gactgllgt~~tctatalla~tte'ggatgctgtgttg~~gtgalltttttggtaaa~t~ttatatggac~a\\tagahlglaal 
algaaa r.caagtattgglltgtallllgcag TCACAA T A TG GAG C~ ~~ > ~ > TTC CG TTTC TGC CAA 
GC CT GAAC T ACC CCTCTTTT AC ACT C CT A TT GA T CT G G T G GACA TT A 'G T G T AGA 
AATGGCCGGATTGAAGTTT'AI41 0221) (tic) (dbSNP '51801159) T AAA TCCTTT 




ga~gl a liagr.l aagr.laacaaa ac l la lilla c la lgc aglag i la lgil
al a aallcctclgcaaaaalgigaga g aecicata ial gicalalg a ~tg~gcag~t~~l
lc~~aa lc  
 
A ' ' "1 1 
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H clla taa t t ta lilia l aaa aatctgccagttgcl tgctgatgca tagaaa
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t t t lit t it lla l I t t i  
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Annotation of TYMS with positions of primers 
relative to variant sequence 
5'UTR VNTR 
ctt.gdgddggCgcggtCg"CCdg ac gg ltCCC"d"gggCgCd 'l'.CC'.lCC<C~>gccaccgC"CClg <C~~ ICC" gg 'Jc C 
»»»cgggtttcctaagactctcagctyt~ccctyygctcc~ltctytYCC.Cdcccylyyctc 
ctgcgmccccclggcgcacgctctclogogcgggggcog<cc>gcg.occcgccg.g Cdgg •• gdggcgg.gCgcgggd 
oggcogogggAAAAGGCGCGCGGA,\GGGGTCCTGCC,\CCGCGCCACTTGGCCTGCCT 
CCGTCCCGICCGCGCCACTTGGCCTGCCTCCGTCCCGCC.GC.GC.CA C. TTC.GC.CTG 
CCTCCG~CCCCCGCCCGCCGCGCCArGCCTG~GGCCGGCTCGGAGC~GCCGCGCCG 
GCCCTTGCCCCCCGCCGCACAGGAGCGGGACGCCGAGCCGCG~CCGCCGCACGGGG 
,\GC~GU.GTACCTGGGG CAGATCCAACACA TCCTC««« CGC 
T G C GGCG~ CAGGAAGGACGAG GG CAGG G GG ACG GG C""C CCTGTCG GT A P CGG GA TG 
CAGGCGCGC~AC,\GCCTGAGAGgtg.cgcc~cgggccCC·.gcgQg.cgQg·.ggCQggadgg~ggQ.Wcg 
cggctgggQdg.gcgc lc gQgagc·.gccggQcgC'.gcgg.ccccg ltlagtcCla~CClc~atcclg<cg>agggaQgggoc 
Qoatcgtootcctcgcottaca gaogoogoaa cgg 
3'UTR indel 
caacagg lc g·.aCaaila lgQc~aa'aloo'ggccttat·.Itgttttt~gC.TTCAGC'GAGAAC.C.CAGACCT-TCGC 
AAAGC. ~CAGGA TTC~TCGAAAAG~TGAGAAAA TT G A TGACT~CAAAG CT G AAGAC TTTGA 
G,," -~ GAAG GGT ACAA T C CG C"" ~ CCAACT A '1 AAAA TGGAAA ' G GC T G TT"' ... '- G G ~ G C 1 T 
TC AAAGGAG CT'CGAAG GAT A ~TG 'CAGT cn T AGG GG TTGGG C 'TGGA TGC CGAG G ~ A 
AAAGTTCPTTTGCTCT MAAGAA'AAAGGAACT AGGTCAAA»» »AA TCTG 
TC CGTGAC CT A TCAGTT Ar AATTTTT AAGGA~G'TTGCCACTGGCAAATG 
I AACTG 'G CCAG TTC~TTC CAT AA T AAAAGGC 'TTGAG TT AACT CACTGAGG' G ~ A T C' G 
ACAA T G C ~ GAG G 1 T A TGAACAAAG ~ G A GGAGAA TGAAA TG T A TG T G CT C ~T AGCAAAAA' 
C. 'A TGT A TGTGCA ~TT'CAA ~ c. cc. ACGT AC~T A T AAAGAAGGT TG G T GAA 1 1 T GACAAG C T 
"" TT TT' G GAAT A PT Tr AG,\A T ,\ TTT' AAGA,\ - n GACAAGG fA P CCC~ CAAA ~ C - GA'G G 
GAG CT GAGT AACACCA ~ CGA T CA TGA T G T AGAG ~GTGGr A TG AAC T" TT AA A G 
( 2 0794 \i tt .~~!l I-lI<lbS NP '" 164 30 ) I TA'TAGP GTTTT A T A TGTTGCT A' AA ~AAAGA 
AGTG-TC~GG,"tc gtococgctttgt,o " ttct gtoctgcoactto,otgc,oog~ccttcotao"atag . tl o"ag.actctcclt 
d.gt"a.O.lglgctgtattctggtttgg atg cta < < < < < < cttHd".gdgt.t"tttt"ga 
",toot"g tgoot"tottttgccototttttotcottttooctgcotclt,tcctcoa""t"t"dtg"OOdttt"99"I.gdgtltttttlttttttt't 
tt""aott"lt.1taaoctt."'.1gygtt"tttt."d"t""tctatgg"otdCC"tlttyccctc""tI.ycltc.Qcdlyytyty.ctlctcta 
at~ o,"'gctt"gonaogcaoggaoaagatgc "ao" coaottcggggttoatcogtg ooa tatt~Atooc~cgt'gcotocc.gat 
aoocoogg ' g 'tgoaogoctatt~tot,otgc,oot'tatg ooaog 'gttaoocoga"coog ga"tt"I 'cc."coagltdtgoaoc" 
"g'tgctta 'i tc .d 
no 
S'
ddggCgcg tCg"C dgacgQltCC "ddQ<l CgCdg'.C '.lCC<C~>9CC ~lcca9 ·.t c
uu9C CQ u u u1uu
' gcgC" ctctclogogcgggggcog<cc>gc . .gC . Cgc
,\ \
CCCGCC. c. c c.nc.Gc.C
T
cccnGC GC GCACAGGAGCGGGACGCCGAGC
\G TGCIIG G  
G C C C C GC II  G C
IIC,\GCCTGIlGAGgtg.cg c~c g ccc·.gcgQg.cgQg·.ggcggg w
gggQdg.gcgclcgQga9C·.gc ggQcgC'.gcgg. l cct g
t otcct ,
'
glc aC ailatgQc~a 'aI,o·ggccttat·.Itg l t~gC. TCAGC'GAGAAC.C.CA GC
II Il C
il II II II A(-
P A CTl
Il AGTTC PT     IlIIAAGAA' AA  GM  > > >> > > A    
 ~
II T  
PC II II I II 'I I I C GII 'I 
II I IT P il  I II l II r II C G C r T' II
 r    
~ t  lI <I b   f'    I   "G P       '  
T C cgc tg c , "otto,otgc,o c tcota " looag .~ctctc
C.l glg e      ." . gt.t
,otogtg, t"t"ttttgco tot ctcon , ctgc,tclt.,t . . odttt.gg.l.gdgtltttttlttt
""~ t.1t~.O t."'.1gUgtt" tt".1d.t""tctatg~.ctd C"tI ty ctc".tI.ucltc.Qc" uututu.ct
"'gc t"gonao oa gatgc"ao"cc"ct cg t oatcogtgo atat ~'tocc~ .









wnTab l ~ 2 3 3 Primer Inform ation for ~na l y"is of varian ts w lth'n the pharm acoqe no. TYMS Dnd DPYD Pr im e r Na me 
jJPYD l'iSI .) ( 
DPYD IV~14 " 
,"PYD 543 ( 
DPYD ;<, " 
:JPYD '" ( 
J I' YD " 
, 
TYMS VNTR " 
lYMS ,., ( 
'VMS '0' " 
SN a PShot ' · Int.r na l Prim e rs 
r<39 1B29U (O l-YD IVS14 tlG>A SNP) 
rs 1e 01159(DPYD 1543V SNP) 
r>1801265 (DPYD K;>9C SNI'I 
f Noo_homo~o ~' t,j lambm repeat 
i-Iuc<ecenllaW 
L e n~th ;m ( " GC % Primer S ~ qu~nc. 5' to 3' .'16 5 il H TG T AAAAC GAC GG CC AG 1 C T TTCA T CAGCACA TTC T GAC 
" ;0 " CACCAACTTA TG CCAATTCTC 
.'Iii 5il ',i; TGT AAAACGACGGCC AGT TICCGTTTCTCCCAACCC 
'" ;0 " GAA TC ATTGATGT GC TGGTG 
n "' '" II TGCTCTCFTAGACTA TCCTCG 
n " " 'TGCC TTACAATGTGTGG AG TG 
CGCG~T TCCT AAGACTCTCAG 
'" ;< ',5 GAGGAIG TGITG GII ICTGCC 
" " ;0 AA TCTG TC CG TGAC CT A TCAG 
n " " TAGCATCCIIAACCACAATACAG 
" N.'A NJA "'CM TCAACAA TCMCAA I CMCAGGCTGACTTTCCACACMC 
" NIA NJA CAA TCAACC T AGC AAG AC C AAAAGGIl TTT A 
" filA NIA CM TCAACAA TCAACAA TCACAAAC TCA T C CAACT 
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Table 2.3.4a: Reaction set-up for multiplex PCR assay of pharmacogenomic variants 
D ............ Stock ,... 1)( (un Final ,.. ·m 
sdH20 (SABAX) N/A VARIABLE N/A 
Go Taq Buffer (Promega) 5x 5 1x 
MgCI2 (Merck) 50mM 1 1.5mM 
dNTPs (Bioline) 5mM 1 200IJM 
Forward Primer of rs3918290, 20IJM 0.5/variant 0.41J M 
rs1801265 and rs1801159 
Reverse Primer of rs3918290, 20IJM 0.5/variant 0.41JM 
rs1801265 and rs1801159 
Go Taq Polymerase (Promega) 5 Units/IJI 0.1 0.5 Units/IJI 
DNA 100ng/1J1 1 4ng/1J1 
Final Volume 251J1 
Table 2.3.4b: General cycling conditions for multiplex PCR assay of pharmacorelevant 
variants 
Denaturation \ 95°C for 5 min 1 cycle 
94°C for 60 s 
Amplification 56°C for 60 s 30 cycles 
72°C for 80 s 
Final Extension 172°C for 7 min 1 cycle 
Table 2.3.5b: Reaction mix for Cycle Sequencing of DPYD variants, rs3918290, 
rs1801265 and rs1801159 
Reagent Stock 1x h,lI) 
CI 
Termination mix (Applied Biosystems) N/A 1 
Big Dye Sequencing Buffer (Applied Biosystems) 5x 2 
Reverse/Forward primer of rs3918290, rs1801265 and rs1801159 20IJM 1 
Purified PCR products -50ng/1J1 3 
sdHP N/A 3 
Final Volume 10 
132 


















Table 2.3.Sc: Cycling conditions for sequencing of DPYD variants 
96°C for 5 min 1 cycle 
96°C for 30 s 
50°C for 15 s 25 cycles 
72°C for 4min 
Table 2.3.6a: Reaction set-up for PCR assay of TYMS VNTR (rs45445694) 
Reaaent Stn~k Coni 1)( (ull Final r. 
sdH20 N/A 14.4 N/A 
Go Taq Buffer 5x 5 1x 
Glycerol (Merck) 50% 2.5 5% 
dNTPs 5mM 1 200IJM 
Forward Primer 20IJM 0.5 O.4IJM 
Reverse Primer 20IJM 0.5 O.4IJM 
Go Taq Polymerase 5 Units/lJl 0.1 0.5 Units/lJl 
DNA 100ng/IJI 1 4ng/IJI 
Final Volume 251J1 
Table 2.3.6b: General cycling conditions for PCR assay TYMS VNTR (rs45445694) 
Denaturation 1 95°C for 5 min 1 cycle 
94°C for 30 s 
Am plification 52°C for 30 s 35 cycles 
72°C for 40 s 

























Table 2.3.6c: Reaction mix for cycle sequencing of TYMS 5' UTR VNTR 
(rs45445694 ) 
Stock Concentration 
Termination mix N/A 
Big Dye Sequencing Buffer 5x 
Reverse primer of rs45445694 20iJM 
Purified PCR products -50ng 
Glycerol 50% 
sdH 20 N/A 
Final Volume 








Table 2.3.6d Cycling conditions for cycle sequencing of TYMS 5'UTR VNTR 
(rs45445694 ) 
98°C for 10 min 1 cycle 
98°C for 1 min 
55°C for 1 min 40 cycles 
72°C for 2 min 
Table 2.3.7a: Reaction set-up for amplification of TYMS 3'UTR insertion/deletion 
(rs16430) 
RAaa~nt J;tock Concentration 1x(ull FinalConcAntration 
sdH 20 N/A 16.9 N/A 
Go Taq Buffer 5x 5 1x 
dNTPs 5mM 1 200iJM 
Forward Prim er of rs 16430 20iJM 0.5 O.4iJM 
Reverse Primer of rs16430 20iJM 0.5 0.4iJ M 
Go Taq Polymerase 5 Units/iJl 0.1 0.5 Units/iJl 
DNA 100ng/iJi 1 4ng/iJ i 
Final Volume 25iJi 
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Table 2.3.7b: Cycling conditions for amplification of TYMS 3'UTR insertion/deletion 
(rs16430) 
Denaturation j 95°C for 5 min 1 cycle 
94°C for 30 s 
Am plification 54°C for 30 s 30 cycles 
72°C for 40 s 
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